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The essentiality of fat was first discovered by Burr (1). The rats in the study were fed dif-
ferent diets, one of which being without any fat. The animals developed symptoms of defi-
ciency such as dermatitis, kidney problems and growth retardation leading to a premature 
death. The issue of fat essentiality was further studied in humans by, among others, Hansen 
and Wiese in  the 1950ties (2). Specifically the importance of omega-3 fatty acids wasn’t 
recognized until the 1980ties, when Holman (3) detected a deficiency syndrome in a girl 
maintained on total parenteral nutrition rich in omega-6 fatty acids but low in omega-3 
fatty acids. The deficiency symptoms comprised of, among others, periods of numbness, 
paresthesia, weakness, inability to walk and impaired vision. Since the eighties considerable 
progress has been made in the understanding of  the physiological functions of essential 
fatty acids (EFA) in animals and humans and their role in chronic diseases. Two of the most 
important fatty acids for the nervous system are docosahexaenoic acid (DHA) from the 
omega-3 group and arachidonic acid (AA) from the omega-6 group. Supplementing for-
mula with these LCPUFA has been found to be beneficial in early infancy (especially DHA 
supplementation), however outcome assessed between the ages of 6 and 24 months usually 
did not demonstrate differences between supplemented and non-supplemented groups (4). 
This age period however is known for its insensitivity to reveal effects of exposures during 
early ontogeny (5), implying that absence of an effect during this period does not preclude 
a possible effect a later age. Currently no data exist on the effect of LCPUFA supplemen-
tation of  formula on developmental outcome at school age. Advantages of another form 
of early nutrition, breastfeeding, at school age have been found consistently, even though 
recent studies have shown that associated factors, such as maternal IQ and SES may play 
a role (6-8). This indicates that LCPUFA supplementation of formula may affect develop-
mental outcome at school age. 
The effect of DHA and AA supplementation in infants early postnatally on develop-
ment at age 9 is the subject of the first part of this thesis. 
The relation between fatty acid status at birth and development at age 9 is the subject of the 
second part of this thesis. 
This chapter gives a short overview of the role of fatty acids in the human body. The 
focus lies on fatty acid metabolism, fatty acids in the cardiovascular system and in growth 
and the role of  fatty acids in  brain development. The chapter also includes a  summary 
of human brain development and features an overview of the test battery used in the study. 
It finishes with the questions addressed in the thesis.
1.1 Fatty acid metabolism
Fatty acids consist of a carbon chain skeleton with a carboxyl group at one end. Fatty acids 
exist in saturated and unsaturated forms, with trans-fatty acids as a special form of indus-
trially saturated fatty acid. The difference between saturated and unsaturated fatty acids lies 
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in the presence of double bonds in their skeleton. The unsaturated fatty acids have at least 
one double bond were saturated fatty acids have none. Polyunsaturated fatty acids (PUFA) 
have a minimum of two double bonds. Different PUFA groups are distinguished, named 
after the number of  the carbon bond at which the first double bond is located counting 
from the carboxyl end of  the molecule. For example: the fatty acids with the first bond 
at the 3rd carbon atom are known as the ω-3 or the n-3 fatty acids, and the fatty acids with 
the first bond at the 6rd carbon atom are known as the ω-6 or the n-6 fatty acids. For this 
thesis the n- notation will be used. PUFA with 20 or more carbon bonds are known as long-
chain PUFA (LCPUFA). Each fatty acid has, aside from the systematic and common name, 
a shorthand notation. The first number is the number of carbon atoms in the molecule, the 
second number, right after the colon, is the amount of double bonds and the last number is 
the location of the first double bond counting from the carboxyl group. See Table 1 for a list 
of the most relevant fatty acids in this thesis. 
Table 1.
Common name Shorthand notation
Linoleic acid 18:2 n-6
α-Linolenic acid 18:3 n-3
Arachidonic acid (AA) 20:4 n-6
Docohexaenoic acid (DHA) 22:6 n-3
Linoleic acid (LA) is the parent fatty acid for the n-6 fatty acids group to which ara-
chidonic acid (AA) belongs and α-Linolenic acid (ALA) is the parent fatty acid for the n-3 
fatty acid group to which docosahexaenoic acid (DHA) belongs (9). The parent EFA can be 
converted into LCPUFA, by alternating desaturation (delta-5 and delta-6 desaturases) and 
chain elongation, see figure 1 (10). These enzymes are limited and similar for both the n-3 
pathway as for the n-6 pathway resulting in a process of competition in which high intake 
of DHA results in a decrease of AA levels (9). 
Omega-3 and omega-6 long-chain fatty acids are conditionally essential, meaning 
that humans can synthesize these fatty acids de novo from their respective precursor, how-
ever due to the limited enzyme availability not in sufficient amounts. This is especially true 
for DHA. This may be concluded from the dependence of DHA levels in the blood on varia-
tions in the diet (11–13). AA seems much more robust to dietary limitations (11,14–16). 
Sources of AA are meat, eggs and poultry. DHA is mainly consumed via fatty fish.
Trans-fatty acids can be found in baked foods and fast foods and also in lower con-
centrations in dairy products. They are incorporated in the body tissues and inversely re-
lated to LCPUFA status (17,18).
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Figure 1. Metabolism and nomenclature of the main LCPUFA’s of the n-6 and n-3 series. Both 
pathways use the same enzymes for desaturation and elongation. 






























1.2  Fatty acids and the cardiovascular system and 
growth
There have been numerous studies on the association between omega 3 fatty acids and car-
diovascular disease at adult age (19–24). In general these studies suggest cardio protective 
effects of omega 3 fatty acids, however definitive conclusions cannot be drawn due to sub-
optimal research designs and the exclusive use of high risk populations. Some of the prob-
lems encountered in these large studies were a high level of drop-out, open-label studies, 
lack of power, lack of control group and problems in checking long-term adherence (25). 
Studies on the association between LCPUFA supplementation at early age and cardio-
vascular indices, such as blood pressure and heart rate, in humans are limited in number and 
vary in quality. The studies differ in duration of supplementation, fatty acid dosage, and lipid 
composition. Inconsistent results are reported. Beneficial effects of LCPUFAs on blood pres-
sure and heart rate have been reported by Forsyth et al (26) and Pivik et al (27), but no effects 
of LCPUFA were found in other studies (28). Asserhoj et al (29) even reported a negative effect. 
A limited number of studies has been carried out on the effect of early postnatal 
LCPUFA supplementation on growth measures and follow-up has not surpassed the age 
of 3 years. Until that age range no effect was found on head circumference, weight, length 
and resulting body mass index (BMI) (4). This also implies no negative effects of LCPUFA 
supplementation on growth in the first three years of life. Breastfeeding on the other hand is 
related to growth. Having been breastfed is associated with a small but consistent reduction 
in obesity risk in later childhood (30).
1.3 Other roles of fatty acids in the body 
The parent EFA and LCPUFA are important components of cell membranes all through the 
body. LA has an important role in the skin where it contributes to the skin’s barrier func-
tion and thereby limits transepidermal water loss. In contrast to LA, only a limited amount 
of ALA gets stored in the body (31). 
EFA make up 20% of human adult dry brain weight, including about 6% for AA and 
8% for DHA. AA is especially important as a second messenger in synaptic signal transduc-
tion. DHA is a major structural lipid of the retinal photoreceptor outer segment membrane. 
In the brain it also plays a role in gene expression, apoptosis (programmed cell death) and 
neuronal development (9,32–35).
LCPUFA can be converted into other useful substances such as eicosanoids (prosta-
glandins, thromboxanes and leukotriens) that play a role in many bodily systems, primarily 
in inflammation, immunity and as messengers in the central nervous system. Eicosanoids 
originating from n-3 LCPUFA differ from eicosanoids originating from n-6 LCPUFA. N-6 
eicosanoids are in general pro-inflammatory and n-3 eicosanoids much less so. The bal-
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ance between these two groups of eicosanoids has implications for many bodily functions. 
A detailed overview regarding these implications is beyond the scope of  this introduction, 
however the interested reader is referred to De Caterina and Basta (10) for an overview. 
A third important function is the role of LCPUFA in gene expression, LCPUFA 
induce changes in gene expression playing a role in various processes such as lipid metabo-
lism and transport as well as development of the nervous system (36).
1.4 Brain development 
The development of the brain starts shortly after conception with the formation of the neural 
tube. The first half of  gestation is a  period characterized by  neural proliferation and pro-
grammed cell death, once neurons have been formed they migrate to their final destination 
(37). A large part of the cortical neurons migrate along specialized radial glial fibers that span 
the entire thickness of the hemisphere (38). Migration peaks between months three and five 
of gestation (39) and is suggested to be finished around week 30 post menstrual age (PMA). 
Migration is also the period during which a large part of the neuronal differentia-
tion takes place, encompassing processes like dendrite and axon formation and the produc-
tion of neurotransmitters and synapses. A process that continues when the final destination 
of the neuron has been reached (38). An important role in the process of neuronal migra-
tion to the cortex is played by the subplate, a transient structure that develops between the 
periventricular white matter and the developing cortical plate (40). This structure is said 
to function alike a ‘waiting room’, forming a temporary goal of afferent fibers heading for 
their cortical destination. While present in the subplate the temporary connections already 
form functionally active circuitries, these most likely play a role in the generation of fetal 
and neonatal behavior (41,42). The subplate is an important structure between the weeks 
24 and 36 PMA after which it begins to decline. Around the age of 6 months postnatal age 
the subplate will have disappeared (40).
Around week 32 PMA age specific characteristics of the future adult brain can be 
recognized. Distinct vertical layers (43) are found as well as the major neurotransmitter 
systems, the most common glia and neuron types (44,45). This is also the period in which 
the cortical gyri and sulci start to develop (46). From this period until the age of 2 years the 
brain undergoes a large growth spurt, at the end of which the brain weighs 80% of the adult 
weight. Important processes during this growth spurt are axonal and dendritic differentia-
tion, axon elimination, synapse formation, myelination and glial cell proliferation (37). 
Between the ages of 2 and 5 years the brain grows relatively little, from 80% to 90% 
of its adult weight (47), this phase is therefore sometimes called the ‘plateau phase’. During 
this phase myelination and synaptic remodeling are particularly active.
Neural connectivity is important for smooth communication between brain regions. 
Smooth communication depends for a large extent on the integrity and maturity of the brain 
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white matter tracts. Several studies have evaluated the development of  white matter and 
found a  steady increase in  the overall white matter volume from childhood to adulthood 
(48,49). Large regional differences are found. For example in  the regional variation in  the 
growth of the corpus callosum, where analyses showed continuous age-related changes in the 
posterior sections however not the anterior sections (48,50). Differences are also found be-
tween the genders, for example in the development of the left inferior frontal gyrus (compris-
ing the pars opercularis, triangularis and orbitalis). Here boys showed a  linear age-related 
increase in the WM volume where girls did not, in the ages between 6 to 17 years (51). 
Volumes of gray matter begin to decline in late childhood or adolescence (48,49,52–
56). This process occurs first in the sensorimotor areas, followed by association areas and fi-
nally occurs in the integration areas such as the superior prefrontal cortex and the posterior 
parietal cortex. The cerebellum shows a more protracted course, decline beginning around 
the age of 16 for boys and slightly earlier for girls (57).
This so called ‘cortical thinning’ is considered to represent two concurrent process-
es: pruning and myelination. The result of these processes is believed to refine connectivity 
and enhance the efficiency and fidelity of signal transmission. It is therefore regarded as 
a marker for maturation (58). 
1.5 Fatty acids in brain development
1.5.1 The role of fatty acid status during pregnancy
Fatty acid status of the fetus depends on maternal dietary intake, both during pregnancy 
and prior pregnancy via maternal fatty acid stores using trans placental transport, and ma-
ternal and fetal LCPUFA syntheses (59–61). Trans placental transport is selective for LCP-
UFA meaning the concentration LCPUFA in the fetal circulation is higher than the con-
centration in the maternal circulation, a process called biomagnification (62). This process 
causes the fetal LCPUFA levels to be up to 400% of the maternal LCPUFA levels (63,64). 
Next to biomagnification the fetus can create its own AA and DHA via synthesization from 
the respective precursors LA and ALA. Fetal and newborn LCPUFA synthesis is signifi-
cantly better for AA than for DHA (63,65). For the latter the high requirements appear not 
to be met until 16 weeks after term (33,66,67). A deleterious effect on fatty acid synthesiza-
tion is caused by smoking, a study by Agostoni reported a diminished maternal capacity to 
synthesize AA and DHA in relation to maternal smoking during pregnancy (68).
The fetus requires a high amount of LCPUFA especially during the last trimester 
of gestation when about 90% of fetal fat deposition takes place (63). To provide the required 
LCPUFA, maternal fatty acids in plasma rise by 50% during pregnancy, which is brought 
about by accelerated break down of maternal fat stores (63,69). In general in the western 
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countries DHA intake is lower than the recommended 450 mg LCPUFA-n3 per day, this 
in contrary to AA intake which appears to be sufficient. This might indicate that both cur-
rent nutritional intake as well as established maternal fatty acid stores are not optimally 
equipped to provide for fetal needs. Evidence suggesting this is found in the slow recovery 
of maternal LCPUFA status after delivery, which is further retarded if the infant is breastfed, 
as well as in  the lower LCPUFA status of  multigravidea in  comparison to primigravidea 
(70). A suboptimal LCPUFA provision during pregnancy could lead to a (relative) LCPUFA 
deficiency in the fetus at birth. 
Studies on the relation between prenatal LCPUFA status and neurodevelopment 
present mixed evidence. Generally, a positive association is found between prenatal AA and 
DHA status and neurodevelopmental outcome during early infancy (71–74). After early 
infancy a subtle yet positive relation is only found between the consumption of fish or DHA 
and not AA with neurodevelopment in some studies (74–85) while no effects were found 
in other studies (86–88). 
Studies on the effect of neonatal trans fatty acids on neurodevelopment are scarce. 
Yet the limited evidence points towards a negative association, both at early postnatal age 
and at 18 months (71,75). The precise mechanisms are as yet unknown however the negative 
association between trans fatty acid status and LCPUFA status may be partly responsible.
1.5.2 The role of fatty acids in the postnatal period 
Breastfeeding is generally accepted as the preferred nutrition for infants. The positive effect 
of breastfeeding is usually attributed to the nutritional value, however recent studies have 
shown that associated factors such higher maternal IQ play a large role (6).
Despite the ability of infants to synthesize LCPUFA from their precursors this abil-
ity does not suffice to fulfill their needs until 16 weeks after term (33,66,67). This may 
explain why in  the absence of  a  dietary source of  DHA, as was usual in  infant formula 
a decade ago, the erythrocyte and plasma DHA concentrations of infants decrease heavily 
in the first 4 months after birth (89). Autopsy studies in infants, having received formula’s 
without DHA and AA, have also shown this drop in LCPUFA on a brain level. This differ-
ence is more pronounced for DHA levels than for AA levels (90-94)
Animal studies have shown that DHA deficiency during development is associated 
with decreased cognitive and behavioural performance (95) and that dietary supplementa-
tion of either DHA or fish oil in the prenatal and early postnatal phase results in an increase 
of DHA in brain tissue which seems to be accompanied by a decrease of AA levels (96-100). 
The functional effects of  early DHA and fish oil supplementation in  animals is unclear. 
Some studies report acceleration of  visual development (101–103) while others report 
poorer auditory and motor development (96,98–100,104,105). Interestingly, for learning 
capacity no differences are reported (97,100).
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Several human supplementation studies have been performed, the recent Cochrane 
review by Simmer (4) reported on 18889 term infants from 15 randomized controlled tri-
als. Despite a large variation regarding type of supplementation, concentration and dura-
tion of supplementation no clear or consistent benefit is found regarding formula supple-
mentation with LCPUFA on visual acuity and neurodevelopmental outcome. 
1.5.3 The role of fatty acids in the brain 
The current knowledge on the role of  LCPUFA in  the developing brain is still limited. 
Literature shows that LCPUFA have a general influence on neuronal membranes and on 
neuronal gene transcription (106,107). In the developing brain LCPUFA accretion starts 
slowly during early fetal development, were it plays a role in the promotion of prolifera-
tion and differentiation of cortical neurons (108,109). During the first two trimesters AA 
accretion is larger than that of DHA (110,111), during the brain growth spurt in the third 
trimester, a period characterized by a high LCPUFA requirement, DHA accretion becomes 
larger than that of AA (33,91,110). At term the brain still contains relatively more AA than 
DHA(110,111). The continuing process of higher DHA accretion after term results in the 
adult brain featuring DHA as the main LCPUFA (91,93,110–112). 
An animal study by  Diau (113) demonstrated that LCPUFA accumulate mainly 
in the cortical grey matter, predominantly in the synaptic membranes, and to a lesser extent 
in the white matter, this replicates earlier studies (9,33). The study by Diau also demon-
strated that the highest concentrations of LCPUFA are found in the basal ganglia, pre- and 
postcentral cortices, hippocampus and thalamus, indicating that LCPUFA intake might 
affect in particular, circuitries involved in sensorimotor integration and memory. 
1.6 Developmental tests used in this thesis 
1.6.1  Neurological examination with special attention to minor 
neurological dysfunction
The examination of Minor Neurological Dysfunction (MND) according to Touwen (114) 
pays special attention to the presence of  MND. Essential in  the diagnostics of  MND is 
the presence of coherent clusters of  signs. Single signs do not have clinical significance, 
however when they co-occur with other signs within a  functional domain they do. The 
examination is organized into eight functional domains: posture and muscle tone, reflexes, 
dyskinesia, coordination, fine manipulative ability, associated movements, sensory deficits 
and cranial nerve functioning. The primary outcome of  the neurological examination is 
General introduction
19
the clinical neurological condition: neurologically normal, simple MND, complex MND 
or neurologically abnormal. A child is considered neurologically abnormal in the presence 
of a clear neurological disorder such as cerebral palsy. Complex MND denotes at school age 
the presence of more than two domains of dysfunction and is the clinically relevant form 
of MND. In an etiological sense it can be considered a borderline form of cerebral palsy 
as it is linked to a chain of pre- and perinatal adversities (5,115). Simple MND denotes 
at school age the presence of one or two domains of dysfunction and is present in about 
15-20% of children. It has little clinical relevance and can be regarded as typical but non-
optimal brain functioning, in other words as a minor neurological difference and not so 
much a dysfunction. A child is classified as neurologically normal when no domains are 
scored as deviant or in case of the isolated presence of a mild dysfunction in reflex activity. 
In addition to the classification into distinct categories, we used the optimality con-
cept to summarize neurological condition. For each of the 64 items in the examination an 
optimal range was identified per age-group (114). The total number of items on which the 
child scored a value within this optimal range formed the neurological optimality score 
(NOS) of this child. It should be realized that there is a conceptual difference between nor-
mality and optimality, as the range for optimal behavior is narrower than that of normal 
behavior (116). The NOS may be regarded as a quantitative and more subtle expression 
of the clinical neurological condition. This also means that the two measures are highly cor-
related (current thesis rho = -0.691, p < 0.0001). The quantitative and precise nature of the 
NOS makes it an excellent instrument to evaluate subtle deviations in neurodevelopmental 
outcome. The NOS has previously been used in infancy and pre-school age (117); in the 
current thesis the NOS principles are applied at the age of 9 years for the first time.
The Touwen assessment has a good intra-rater, inter-rater and test-retest reliability 
(115). Its construct validity is reflected by the differential relationship for simple and com-
plex MND with prenatal and perinatal adversities: adverse conditions during early life have 
a weak to moderate relationship with simple MND and a strong correlation with complex 
MND (5,118). Predictive validity is good, i.e. the severity of MND at 9 years is related to 
the risk of MND at 12 and 14 years and with learning and behavioral problems at 9 and 14 
years (5,119,120).
1.6.2 Examination of cognitive development
The cognitive test battery was designed to give a broad overview of cognitive functioning, 
focusing on those functions most likely to reflect an effect of LCPUFA supplementation, 
whilst keeping to time restraints. The earlier mentioned study by Diau (113) showed that 
LCPUFA was especially present in the basal ganglia, hippocampus, thalamus, cerebellum, 
precentral, postcentral, prefrontal and occipital cortices, areas that are of importance for 
intelligence, executive function, attention, learning and memory.
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The cognitive test battery consisted of  the Wechsler Abbreviated Scale of  Intelli-
gence (WASI, (121)), subtests from the Nepsy – A developmental neuropsychological as-
sessment (Nepsy, (122)), subtests from the Test of Everyday Attention-Children’s version 
(TEA-Ch, (123)) and subtests from the Children’s memory Scale (CMS, (124)).
The WASI is an intelligence test especially designed for a brief and reliable assess-
ment of full, performance and verbal IQ and is considered a valid screening instrument 
(125). Because of its brevity it is not recommended to be used as a full individual IQ screen-
ing instrument, however it is very useful for scientific purposes focusing on comparisons 
on group level (126). 
The Nepsy (122) is designed to reliably assess neuropsychological functioning 
of children in the ages between 4 and 12 years old and focuses on five domains: attention-
executive function, language, sensorimotor functions, visuospatial functions and learn-
ing and memory. Of these scales attention-executive function, language and learning and 
memory were used in the current thesis.
Attention was assessed using the Tea-Ch (123), a standardized and valid test de-
signed to assess selective attention, sustained attention and switch attention in  children 
aged 6 to 16 years old. Selective attention is considered to be ‘a capacity to enhance the 
processing of particular target characteristics regardless of spatial location’, sustained at-
tention is considered to be ‘the capacity to maintain a particular processing set over time’ 
and attentional control/switch attention (also called spatial attention): ‘the capacity to move 
attention within space’(127) 
To provide additional information on verbal memory the Word Pairs subtest of the 
Children’s Memory Scale was used (124).
At the time of testing no Dutch versions nor Dutch norms were available for the 
WASI, NEPSY, Tea-Ch and the CMS. These tests were therefore translated to Dutch by the 
researchers and the original norms were used. This is usually not advised however since the 
goal of the current thesis does not lie in creating individual profiles of neuropsychological 
functioning but in comparing groups of individuals having received identical testing and 
scoring this is considered to be acceptable.
1.6.3 Examination of behavioural development
In order to examine behavioural development three questionnaires were used. Firstly the Child 
Behaviour Check List (CBCL), secondly the Teacher Report Form (TRF) and lastly a Question-
naire on ADHD. The CBCL and TRF are widely used instruments that assess a broad range 
of competencies and problems. Reliability and validity are well established (128). The differ-
ence between the questionnaires lies in the respondent. For the CBCL this is de parent and for 
the TRF the teacher. The scales include 120 specific problem items and 20 competence items. 
The respondent rates the problem items over the past 6 months as 0 = not true, 1 = somewhat 
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true and 2 very true. These problem items are consecutively scored on statistically derived 
syndrome scales and on DSM oriented scales. For the current thesis, the syndrome scales were 
used: aggressive behaviour, anxious/depressed, attention problems, delinquent behaviour, so-
cial problems, somatic complaints, thought problems and withdrawn/depressed and addition-
ally on the composite scales: internalizing, externalizing and total problems. 
1.6.4 Examination of anthropometry and blood pressure 
As part of the anthropometric evaluation weight, length and head circumference were mea-
sured. During assessments situated at the hospital, weight was measured using a calibrated 
radwag scale, body length using a standard stadiometer (seca) and head circumference using 
a tape measure. During assessments situated at the participants home, weight was measured 
using an available measuring scale and body length and head circumference using a tape 
measure. Statistical tests confirmed the lack of differences between the two locations. Con-
secutively, Body Mass Index (BMI) was determined using international standards taking 
gender and age into account (129). Blood pressure as well as heart rate was measured imme-
diately following a 15 minute rest period, measurement took place on the left arm with the 
child sitting on a chair and the arm resting on a table. An automated blood pressure monitor 
was used (Datascope Accutorr plus) with a small adult cuff (10.6 – 23.9 cm size bladder). 
This procedure was performed twice during the assessment with an hour in between. Heart 
rate, systolic and diastolic blood pressure were recorded as the mean of the two readings.
1.7 Specific questions addressed in this thesis
This thesis consists of  two main parts. The first part concerns the results of  the double 
blind randomized trial focused on the effect of 2 months of postnatal LCPUFA formula 
supplementation on neurodevelopment at age 9. For a flowchart of the Groningen LCPUFA 
project see fig 1 chapter 2. The following research topics will be discussed:
 — Is 2 months LCPUFA supplementation beneficial for neuro-motor development, at the 
age of 9 years. 
 — Is 2 months LCPUFA supplementation beneficial for cognitive and behavioural devel-
opment at the age of 9 years
 — Is 2 months LCPUFA supplementation beneficial for cardiovascular and anthropomet-
ric development, expressed in blood pressure heart rate weight height BMI and head 
circumference, at the age of 9 years
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The second part of  this thesis concerns the relation between neonatal fatty acid 
status and neurodevelopmental outcome at age 9. The following research questions will be 
evaluated:
 — Is there an association between DHA AA and transfatty acid status at birth and neuro-
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2.1 Abstract
Long-chain polyunsaturated fatty acid (LCPUFA) supplementation 
of formula can have beneficial effects on neurodevelopmental outcome 
in early infancy, but uncertainty exists regarding effects after 6 months. 
The current study is the first to investigate whether consumption 
by term infants of formula containing LCPUFA for the first two months 
after birth improves neurological condition of these children at 9 years 
of  age.  A  prospective, double-blind, randomized control study was 
performed in two groups of healthy term infants: a control group with 
standard formula (CF, n169) and a LCPUFA-supplemented group (LF, 
n146). A breastfed group (BF; n159) served as a reference. At 9 years, 
children were neurologically assessed according to Touwen, resulting 
in a Neurological Optimality Score (NOS) and information on sever-
ity and type of  minor neurological dysfunction (MND). Information 
on potential confounders was collected at  enrolment and follow-up. 
Multivariate analyses were carried out to evaluate the effect of nutrition 
while adjusting for confounders. Attrition (28%) was selective: drop-
outs in the LF group were more often boys and had a significantly lower 
mental developmental index at 18 months. Neurological optimality and 
severity and type of MND at 9 years did not differ between the two for-
mula groups. Children in the BF group showed significantly less often 
fine manipulative dysfunction than formula-fed children. In conclu-
sion, LCPUFA supplementation of formula during the first two postna-
tal months in healthy term infants does not alter neurological function 
at school age. The study confirmed that breastfed infants have a slightly 
better neurodevelopmental outcome than formula-fed infants.
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2.2 Introduction 
Long-Chain Poly Unsaturated Fatty Acids (LCPUFA) have become a major focus of atten-
tion in  the field of  infant nutrition and development. The Cochrane reviews of  the group 
of  Simmer (1,2) indicated that supplementation of  formula with LCPUFA, in  particular 
docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid (AA; 20:4n-6), in general does 
not affect motor, visual and cognitive outcome. However, when the age at which the child 
is assessed is taken into account the results are less straightforward. Outcome of LCPUFA 
supplemented formula groups (especially DHA supplementation) is better in early infancy, 
but studies which assessed outcome between 6 and 24 months usually did not demonstrate 
differences between supplemented and non-supplemented groups (1). The latter age period 
is, however, known for its insensitivity to reveal adverse effects of  exposures during early 
ontogeny (3). Thus, the absence of an effect between 6 and 24 months does not preclude an 
effect at later age. Currently data on the effect of LCPUFA supplementation of formula on 
neurodevelopmental outcome at school-age are lacking.
The present study aims at  investigating whether consumption by  term infants 
of  formula containing LCPUFA for the first two months after birth improves the neu-
rological condition of these children at 9 years of age. Neurological development is one 
of  the domains in  which the early beneficial effects of  LCPUFA manifested itself. The 
study is an extension of the original Groningen LCPUFA-study, a randomized controlled 
trial on the effect of supplementation of formula with LCPUFA during the first two post-
natal months. At the age of 9 years a standardised and age-specific neurological examina-
tion was carried out, which specifically assesses Minor Neurological Dysfunction (MND). 
MND is considered a valid measure of neurological condition that shows a strong rela-
tionship with pre- and perinatal adversities (3). Earlier Lanting et al (4) reported that 
breastfeeding was associated with less MND at  school age than formula feeding. The 
primary outcome measure of the current study was the Neurological Optimality Score 
(NOS). The NOS uses the optimality concept to summarize neurological condition; it 
provides a sensitive measure of the child’s overall neurological status. Secondary outcome 
measures were clinical neurological condition in terms of severity and type of MND. Two 
major forms of MND can be distinguished, simple and complex MND. Simple MND can 
be regarded as a typical but non-optimal form of brain function, whereas complex MND 
is the clinically relevant form of MND.
Based on the literature, we hypothesize that the LCPUFA supplemented children 
perform better than the children who received standard formula and that breastfed chil-
dren perform better than the formula fed children. A better performance will be reflected 
in a higher NOS, less and less severe MND, and a lower prevalence of specific neurological 
dysfunctions. The effect of gender on relationships between postnatal supplementation and 
neurological outcome was also determined as previous studies suggested the possibility 





Details of  the study design have been described previously(6). Mothers of 314 infants 
chose to bottle feed their child and 160 opted for breastfeeding. The infants receiving 
formula were randomized into  a  standard formula group (control formula, CF, n169) 
and  a  LCPUFA supplemented formula group (LF, n145). Standard formula consisted 
of Nutrilon Premium®. For the supplemented formula, the lipid fraction of Nutrilon Pre-
mium® was enriched with 0.45% (by wt) AA and 0.30% (by wt) DHA. The duration of sup-
plementation was 2 months. In case breastfeeding stopped prior to 2 months, the infant 
received LCP-supplemented formula till the age of 2 months and, remained in  the BF 
group. All formula-fed infants received control formula between 2 and 6 months. The 
children underwent neurodevelopmental assessment at  3 and 18 months of  age (6,7). 
Follow-up was achieved in 84% (3 months (6)) and 92% (18 months (7)) of the  riginal 
groups. All children seen at the 18 months follow-up were eligible for re-testing at 9 years. 
At the 9 year follow-up, both parents and examiners were unaware of the type of formula-
feeding the infant had received. The examiners also were blind to the type of milk fed 
during the first eight weeks.
2.3.2 Procedures 
Neurological condition of the children was evaluated with the examination according to 
Touwen (1979) (8), which is a standardised, age specific assessment designed for the as-
sessment of minor neurological dysfunction (MND). Essential in the diagnostics of MND 
is the presence of coherent clusters of signs. Single signs do not have clinical significance, 
signs only have significance when they co-occur (cluster) with other signs within a func-
tional domain. The examination is organized into eight functional domains: posture and 
muscle tone, reflexes, dyskinesia, coordination, fine manipulative ability, associated move-
ments, sensory deficits and cranial nerve functioning. The examination results in a clinical 
classification: normal, simple MND, complex MND or abnormal. A child is considered 
neurologically abnormal in the presence of a clear neurological disorder such as cerebral 
palsy. Simple MND denotes the presence of one or two domains of dysfunction and is 
present in about 15–20% of children. It has little clinical relevance and can be regarded as 
typical but non-optimal brain functioning, in other words as a minor neurological differ-
ence. Complex MND denotes the presence of more than two domains of dysfunction and 
is the clinically relevant form of MND. In an aetiological sense it can be considered a bor-
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derline form of cerebral palsy as it is linked to a chain of pre- and perinatal adversities 
(3,9). A child is classified as neurologically normal when no domains are scored as deviant 
or in case of the isolated presence of a mild dysfunction in reflex activity. 
The neurological examination according to Touwen has  a  good intra-rater, inter-
rater and test-retest reliability, the kappa statistics of the three forms of reliability for neu-
rological classification ranged between 0.71 and 0.83 (9). Its construct validity is reflected 
by the differential relationship for simple and complex MND with prenatal and perinatal 
adversities: adverse conditions during early life have a weak to moderate relationship with 
simple MND and a strong correlation with complex MND (3,10). Predictive validity is good; 
this is reflected by the relation between the severity of MND at 9 years and the risk of MND 
at 12 and 14 years and that of learning and behavioural problems at 9 and 14 years (3,11,12). 
The study’s primary outcome parameter was the Neurological Optimality Score 
(NOS). The NOS uses the optimality concept to summarize neurological condition and 
provides a sensitive measure of the child’s overall neurological status. The sensitivity of the 
NOS to detect effects of early nutrition may be illustrated by the study of Bouwstra et al.(13) 
which demonstrated that prenatal fatty acid status was related to NOS at 18 months, but not 
to outcome measured with the Bayley Scales of Infant Development (BSID). For 64 items, 
representing the entire neurological examination, an optimal range was identified (see on-
line supplemental Table 1). The total number of items with a value within the predefined 
optimal range formed the neurological optimality score of a child. It should be realized that 
there is a conceptual difference between normality and optimality, as the range for opti-
mal behaviour is narrower than that of normal behaviour (14). The NOS may be regarded 
as a quantitative and more subtle expression of  the clinical neurological condition. This 
also means that the two measures are highly correlated (15) (current study rho  =  -0.691; 
p < 0.001). The quantitative and precise nature of the NOS makes it a suitable instrument to 
evaluate subtle deviations in neurodevelopmental outcome. The NOS has previously been 
used in infancy and pre-school age; in the present study NOS principles are applied for the 
first time at the age of 9 years. 
Data on pre- and perinatal conditions had been collected during enrolment with the 
help of the Obstetrical Optimality Score (OOS).The OOS describes the obstetrical condi-
tions ranging from the parents’ socio-economic status to the infant’s condition immediately 
after birth (15). At the assessment of 18 months maternal verbal intelligence (IQ) was esti-
mated using a very abbreviated version of the Wechsler Adult Intelligence Scale (WAIS III), 
limited to the subtests information and vocabulary (16). Social condition was documented 
with the Home Observation for Measurement of the Environment (HOME) inventory (17). 
The HOME contains 45 items clustered into 6 subscales: Parental Responsivity, Acceptance 
of Child, Organization of the Environment, Learning Materials, Parental Involvement, and 
Variety in Experience. At the 9 year follow-up information was collected on parental educa-
tion and profession, the child’s medical history, family composition and nutritional habits. 
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Depending on the wish of the participants, the assessment was carried out in the 
hospital or at home. This study was conducted according to the guidelines laid down in the 
Declaration of Helsinki and all procedures involving human subjects were approved by the 
Ethics Committee of  the Groningen University Hospital. Written informed consent was 
obtained from all subjects. The trial is registered under ISRCTN52788665.
2.3.3 Statistical analysis 
Statistical analysis focused on differences in neurological outcome between the two ran-
domized formula groups. In addition differences between the breastfed group and the for-
mula groups were analysed. Specific attention was paid to the effect of site of investigation 
and maternal estimated verbal IQ. Neurological classification, specific clusters of dysfunc-
tion and NOS were not normally distributed. Univariate analyses were performed with the 
Mann-Whitney U test and the Kruskall-Wallis test. 
In order to analyse the effect of nutritional group on neurological classification and 
type of dysfunction while taking into account the role of potential confounders logistic re-
gression analyses were performed. The following confounders, associated with neurologi-
cal outcome at p < 0.20, were entered into the analyses: gender, maternal smoking during 
pregnancy, duration of the second stage of delivery, birthweight, OOS, maternal hyperten-
sion during pregnancy, Apgar score 3 minutes after birth, and maternal educational level. 
To investigate the effect of  nutritional group and the above mentioned confounders on 
NOS multiple linear regression was applied to the NOS transformed to the fifth power. This 
transformation to normality was identified by the Box-Cox method applied to regression 
model residuals (the NOS was skewed to the left). 
The multivariate analyses on the effect of nutritional group were carried out in two 
steps. In the first analysis the effect of the type of formula was assessed, in the second analy-
sis the difference between formula and breastfeeding was evaluated. A p-value 0.05 or less 
was considered statistically significant. Statistical analyses were performed using SPSS 14.0 
for Windows (SPSS, Inc, Chicago, IL).
2.4 Results 
All children who were tested at 18 months were invited for follow-up at 9 years (n436); 341 
of the 474 children of the original study agreed to participate, 91 children in the LF-group 
(63%), 123 children in the CF-group (73%) and 127 children in the BF-group (79%; Figure 
1). Obstetrical data of the study groups and sociodemographic characteristics of the par-
ents are described in Table 1.
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In general, obstetrical and social characteristics of the children who were and who were 
not assessed at 9 years were comparable. Yet, children who were not assessed at 9 years had 
shown significantly more often normal-optimal general movements at 3 months than those 
who had been assessed, meaning that children with an optimal neuromotor condition in early 
infancy were underrepresented in the follow-up of the three groups at 9 years (p = 0.003). In 
addition, attrition in the LF group was more selective than in the other groups. First, in the 
LF-group more boys did not take part in the follow-up (35 and 17 girls) compared to the BF-
group (15 boys and 17 girls) and the CF-group (24  boys  and 17 girls). Second, the mental 
developmental index of the Bayley Scales of Infant Development (18,19) at 18 months of the 
children of  the LF group who were not assessed at 9 years was significantly lower than that 
of LF-children who did participate in the follow-up at 9 (p  =  0.007). A similar selective attrition 
was not present in the CF and BF groups. 
Figure 1. Flow diagram of children enrolled in the study and followed up until 9 years of age. 
* for more detailed information see (7).
474 healthy infants enrolled at birth
Control formula for 2 
months 
N=169














6 lost to follow -up*
10 lost to follow -up*
12 lost to follow -up*
20 lost to follow -up
7 withdrew consent
35 lost to follow -up
9 withdrew consent




Table 1. Obstetrical and social characteristics of the three groups assessed at 9 years. 
Variable BF group (n127) LF group (n91) CF group (n123)
Retention (% of original study groups) 79% 63% 73%
Gender: boys/girls 64/63 42/49 71/52
Duration second stage of the delivery (minutes), 
median (range)
25 (2–138) 22 (1–120) 22 (1–146)
Birth weight (g), mean (SD) 3588 (436) 3527 (498) 3518 (473)
Apgar score 3 minutes after birth, median 
(range)
10 (5–10) 10 (7–10) 10 (7–10)
Maternal education *
–high (university education or vocational 
college), n (%) 
–medium (college graduate or junior vocational 
college), n (%)










Presence of maternal smoking during pregnancy, 
n (%) #
25 (20%) 31 (34%) 44 (36%)
Presence of maternal hypertension during 
pregnancy, n (%)
11 (9%) 11 (12%) 21 (17%)
HOME, median (range) 44 (39–45) 43 (32–45) 43 (35–45)
OOS, median (range) 60 (43–69) 59 (50–67) 59 (49–67)
* significant difference between all groups p = 0.001; # significant difference between BF and LF/CF com-
bined p = 0.003.
OOS = Obstetrical Optimality Score; HOME = Home Observation for the Measurement of  the Environment 
(HOME) inventory; BF = Breastfed group; LF = LCPUFA supplemented group; CF = Control group.
Neurological condition at 9 years was not affected by the site of investigation (in the 
hospital or at home), by current consumption of fish (dichotomized as at least once a week 
or less than once a week) and maternal verbal IQ. The NOS of children in the LF and CF 
groups did not differ, in both groups the median NOS score was 57. The NOS of formula-
fed children (LF and CF groups) was significantly lower than that of breastfed children 
(median values 57 and 58 respectively, Mann-Whitney, p  =  0.008; see also Table 2 for more 
specifics on the BF-group).
Table 2. Duration of exclusive breastfeeding and Neurological Optimality Score 
Duration of exclusive breastfeeding 3–5 weeks 6–8 weeks > 8 weeks
Number of children 25 23 62
NOS (median (range)) 58 (51–63) 58 (50–63) 58 (47–64)
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Multiple regression (Table 3) confirmed that the NOS was not affected by  LCPUFA 
supplementation. The analysis revealed an interaction between gender and type of feeding: girls 
who had been breastfed had a higher NOS than girls who had been formula fed. Other factors 
associated with a higher NOS were higher birthweight and an OOS above the 10th percentile.
Table 3. Results of linear regression analysis of factors contributing to the normalized NOS (the 
fifth power of NOS/50). 
Variables Effect P-value 95%-Confidence interval
Type of feeding within gender
males LF vs CF (reference) 0.173 0.137 ‒0.055 , 0 401
BF vs CF 0.141 0.162 ‒0.057 , 0.340
BF vs LF ‒0.031 0.788 ‒0.261 , 0.198
females LF vs CF ‒0.100 0.389 ‒0.328 , 0.128
BF vs CF 0.238 0.029 0.024 , 0.452
BF vs LF 0.338 0.002 0.122 , 0.555
Gender within type of feeding
CF female vs male 0.367 0.001 0.156 , 0.578
BF female vs male 0.464 0.001 0.262 , 0.665
LF female vs male 0.094 0.450 ‒0.150 , 0.338
Birthweight (kg) 0.147 0.032 0.012 , 0.282
OOS: above vs below the 10th percentile 0.211 0.075 ‒0.021 , 0.443
n330; R2 = 0.14; intercept for a CF male with birthweight 3.5 kg and OOS above P10: 1.7265; BF / LF / CF: 
Breastfed / LCPUFA supplemented / Control group; OOS = Obstetrical Optimality Score
The effects presented in  Table 3 are on the transformed scale of  NOS. An effect 
of size, for example, 0.4 on the transformed scale can be interpreted on the original scale 
as follows. A NOS value of 57 transforms to (57/50)5  =  1.9254, increasing this by 0.4 gives 
2.3254, transforming this back to the original scale gives 50 × 2.32540.2  =  59.2. Note that 
as the width of most confidence intervals in Table 3 is below 0.4, the CI width thus be-
comes about 2 points on the original NOS scale. The NOS at 9 years showed a statistically 
significant association with the mental developmental index of the Bayley Scales of Infant 
Development at 18 months (Spearman rho  =  0.193, p < 0.0001). 
Forty six to 54% of children had a normal neurological condition, 36–39% showed 
simple MND and 10-15% of children had complex MND. Neurological classification did 
not differ between the randomized formula groups. Children in the BF group tended to 
have a slightly better neurological condition than the children in the formula fed groups, 
but the difference did not reach statistical significance (p  =  0.17; Table 4).
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Neurologically normal 68 (54%) 44 (48%) 56 (46%)
Simple MND 46 (36%) 35 (39%) 48 (39%)
Complex MND 13 (10%) 12 (13%) 19 (15%)
No statistically significant differences were present between the groups
BF = Breastfed group; LF = LCPUFA supplemented group; CF = Control group
LF and CF groups did not differ in the prevalence of specific types of dysfunction. 
Children of the BF group however, showed significantly less often fine manipulative dys-
function than formula fed children (BF:16%, LF 30%, CF31%; BF versus formula groups, 
p  =  0.002), this was confirmed in multivariate analysis (Table 5) with the following contrib-
uting factors: OOS below the 10th percentile, male gender, maternal smoking during preg-
nancy and the duration of the second stage of delivery. Breastfed and formula fed children 
did not differ in the prevalence of other types of neurological dysfunction.
Table 5. Results of logistic regression analysis of factors contributing to fine manipulative dysfunc-
tion (explained variance of 18.5%) 













Male gender 2.151 0.010 1.2 , 3.9
OOS below the 10th percentile 7.271 0.001 2.3 , 23
Maternal smoking 1.935 0.034 1.1 , 3.6
Duration of the 2nd part of the delivery 0.989 0.032 0.98 , 1
BF = Breastfed group; LF = LCPUFA supplemented group; CF = Control group;
OR-Odds Ratio; CI = Confidence Interval; OOS = Obstetrical Optimality Score
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2.5 Discussion 
The present study indicated that consumption by term infants of formula containing LCP-
UFA for the first two months after birth did not affect neurological condition at 9 years. The 
study also revealed that fine manipulative ability of breastfed children was better than that 
of formula fed children.
A major limitation of the study is its attrition. Overall attrition was 28%, which – 
over a period of 9 years – can be regarded as relatively favourable (20). However, a major 
problem in the current study was the selective nature of attrition, that is, a selective loss 
of boys and children with a worse cognitive development at 18 months in the LF group. 
The selective attrition interfered with the randomized design of the study. While the mul-
tiple regression analysis can alleviate the effect of attrition if the missingness of data de-
pends only on known covariates, it cannot annihilate the effect of severe (“missing not 
at random”) attrition.
Some of the breastfed children received a few weeks formula supplemented with 
LCPUFA (Table 2). This may be considered a limitation as it may have influenced any dif-
ferences between the supplemented formula group and the breastfed group. However, the 
finding that the neurological condition of the LF-group did not differ from the CF-group, 
reduces the likelihood that differences between LF-group and BF-group were affected 
by the mixed composition of the BF-group. 
The prevalence of MND in the present study is another point which deserves meth-
odological attention. The prevalence is higher than indicated by earlier estimations of MND 
in  the general population (3). This may raise questions regarding the representativeness 
of the current sample of healthy full-term infants. However, neurological evaluation of these 
groups at  3 months indicated that neurological status was representative for the general 
population (6,21). Possibly, the relatively high prevalence of MND in the present study re-
flects the general trend of worsening neuromotor condition in the last decades (22). 
The strengths of the study are its randomized design and its assessor-blinded evalu-
ation with an internationally recognized, sensitive technique to evaluate neurological con-
dition (4,23-26). Based on the width of the confidence intervals, it is concluded that the LF 
versus CF differences do not exceed 2.2 points on the NOS scale.
This is the first study reporting the effect of  supplementation of  formula with 
LCPUFA in  healthy term infants on neurological condition at  school age. Using the 
NOS,  a  sensitive indicator of  neurological condition, an effect of  2 months postnatal 
LCPUFA supplementation on neurological status at 9 years could not be demonstrated. 
Bearing in mind the fact that the LF group suffered from selective attrition of children 
with a lower mental developmental index at 18 months, the current study indicates that 
LCPUFA supplementation during the first two postnatal months does not promote neu-
rological condition at school age. 
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The current finding of a subtle positive association between breastfeeding and neu-
rodevelopmental outcome, and neurological condition in particular, is in line with reports 
of  others (4,27,28). The association between breastfeeding and neurological outcome was 
less strong than previously reported by Lanting et al. (1994) (4), which may be attributed to 
differences in the populations studied (Lanting et al: a mix of high risk and low risk infants; 
current study: healthy full term infants) and the quality of the breastfeeding data (Lanting et 
al: retrospectively collected information; current study: detailed prospective information). 
Der et al.(29) was able to demonstrate that maternal IQ accounted for major part of the as-
sociation between breastfeeding and developmental outcome in terms of IQ. In the current 
study, a subtle association between breastfeeding and fine manipulative ability remained, also 
when estimated maternal verbal IQ was taken into account. Fine manipulative ability is me-
diated especially by cortical-subcortical networks. These networks do not only play a role 
in sensorimotor aspects of motor programming, movement planning, program selection and 
motor memory but also in cognitive functions, such as intelligence (30,31). This means that 
the association between breastfeeding and better fine manipulative ability corresponds to 
reports of others of an association between breastfeeding and higher IQ (28). Interestingly, 
the NOS data indicated that especially girls profit from the beneficial effect of breastfeeding. 
This gender specific effect may be explained by shared genome, and, albeit less likely, gender-
specific differences in metabolism of α-linolenic acid (ALA): adult women have a higher con-
version rate of ALA to eicosapentaenoic acid and DHA than adult men (32). 
In conclusion, the current study indicates that LCPUFA supplementation of  for-
mula during the first two postnatal months in healthy term infants does not promote neu-
rological condition at school age. In addition, the study confirmed that breastfed infants 
have a  slightly better neurodevelopmental outcome than formula-fed infants – reflected 
in the present study by a reduced prevalence of fine manipulative dysfunction. Finally, the 
study underscores the need of  the evaluation of  selective attrition with respect to early 
developmental data in studies assessing the effect of early nutrition on long term develop-
mental outcome.
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2.6 Online supplemental Table 1 
Neurological Optimality Score of the GOM in children aged 9 years
Items Criteria
Cluster Posture and Muscle Tone
–  sitting, standing and walking
–  posture while sitting
–  extending arms in pronation and supination 
while sitting
–  voluntary relaxation
–  muscle strength in head, trunk, arms and legs
–  muscle tone of the head and trunk
–  muscle tone of the arms and legs
–  range of the head, trunk, arms and legs
–  posture while standing
–  posture while walking
–  walking on toes and on heels
–  ability to perform independently
–  typical posture of  head, trunk, arms and legs
–  ability to stabilize the arms in space 
–  easy
–  age-adequate strength
–  normal muscle tone
–  normal muscle tone
–  typical range
–  typical posture of the head, trunk, arms and legs
–  typical posture of the head, trunk, arms and legs
–  able to walk on toes and on heels 
Cluster Reflexes
–  reflex threshold of the biceps muscle, triceps 
muscle, quadriceps muscle and Achilles tendon 
–  reflex intensity of the biceps muscle, triceps 
muscle, quadriceps muscle and Achilles tendon
–  foot sole response
–  plantar grasp
–  abdominal skin reflex
–  normal reflex threshold 
–  normal reflex intensity
–  plantar flexion or no response, symmetry 
–  bilaterally absent
–  symmetrically present
Cluster Involuntary Movements
–  presence of choreiform movements during test 
of extended arms in sitting 
–  presence of athetotiform movements during test 
of extended arms in sitting 
–  presence of tremor movements during test 
of extended arms in sitting 
–  Test of involuntary movements while standing: 
distal choreiform movements
–  Test of involuntary movements while standing: 
proximal choreiform movements
–  Test of involuntary movements while standing: 
athetotiform movements
–  Test of involuntary movements while standing: 
tremor
–  Choreiform movements of the eyes during 
fixation and pursuit 
–  Choreiform movements of the face during 
fixation and pursuit 
–  Presence of choreiform movements during 
sticking out the tongue 
–  no 
–  no 
–  no 
–  no 
–  no 
–  no 








–  kicking with the lower leg while sitting
–  being pushed while sitting
–  being pushed while standing
–  Romberg test
–  diadochokinesis
–  finger-nose test 
–  fingertip-touching test
–  walking on a straight line 
–  standing on one leg 
–  hopping on one leg
–  knee-heel test 
–  age-adequate performance 
–  age-adequate ability to keep balance
–  age-adequate ability to keep balance
–  ability to stand still or only move toes
–  age-adequate performance
–  age-adequate performance 
–  age-adequate performance 
–  age-adequate ability to keep balance
–  ability to maintain balance for 20 seconds on 
each leg
–  ability to hop 20 consecutive times on each leg
–  correct placing and straight sliding of both legs 
Cluster Fine Manipulative Ability
–  finger opposition test, smoothness
–  finger opposition test, transition
–  circle test, opposite direction
–  circle test, same direction
–  circle test, transition
–  follow a finger test
–  age-adequate 
–  age-adequate 
–  age-adequate 
–  age-adequate 
–  age-adequate 
–  age-adequate 
Cluster Associated Movements
–  mouth-opening-finger-spreading phenomenon
–  diadochokinesis
–  finger opposition test
–  walking on toes





–  age-adequate 
Cluster Sensory Deficits
–  graphesthesia
–  kinesthesia 
–  sense of position
–  vision, need of spectacles




–  no need 
–  typical 
Cluster Cranial Nerve Functioning
–  facial motility
–  position of the eyes
–  fixation of the eyes
–  pupil reaction
–  pursuit movements of the eyes
–  nystagmus
–  tongue motility
–  speech
–  pharyngeal arches
–  visual fields
–  normal motility
–  absence of strabismus, heterophoria or other 
abnormalities of the position of the eyes
–  normal
–  normal pupillary reactions
–  smooth movements
–  absent
–  typical motility
–  typical speech
–  normal symmetrical reaction
–  typical size
Quality of walking
–  gait width, gait quality and heel-toe gait –  normal gait width, gait quality and heel-toe gait
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3.1 Abstract 
Aim: Long-chain polyunsaturated fatty acid (LCPUFA) formula sup-
plementation may be beneficial for cognitive development. This study 
aimed to investigate the effect of  LCPUFA formula supplementation, 
primarily on cognition and secondarily on behaviour at 9. Special at-
tention was paid to a potentially modifying effect of maternal smoking 
during pregnancy. 
Method: A double-blind, randomized control study was performed 
in  healthy term infants: a  standard formula control group (CF, n = 169) 
and a LCPUFA-supplemented group (LF, n = 146). A breastfed group (BF; 
n = 159) served as an additional reference. At 9 years, 72% of children (52% 
male) underwent extensive cognitive and behavioural testing. 
Results: An interaction between infant nutrition and smoking 
during pregnancy was found. In children exposed to smoking during 
pregnancy LF was associated with higher mean scores on verbal IQ 
(p = 0.007) and learning and memory (p = 0.006), in  children not ex-
posed to smoking during pregnancy LF was associated with lower mean 
scores on verbal memory (p = 0.003). The LF group scored worse than 
the CF group on executive function (p = 0.001). Breastfeeding was as-
sociated with better performance on IQ (p = 0.005).
Interpretation: No consistent beneficial effect of LCPUFA for-
mula supplementation on cognitive development in  term infants was 
found. The study confirmed that breastfeeding is associated with better 
cognition. 
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3.2 Introduction
Long-term developmental effects of supplementing formula with long-chain polyunsatu-
rated fatty acids (LCPUFA) remain a  matter of  debate. LCPUFA are essential, the most 
important are docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid (AA; 20:4n-6). 
They are present in breastmilk, but a decade ago not in standard infant formulae. 
Young infants have a high DHA and AA need and a limited capacity to synthesize 
these fatty acids,(1) reflected by declining LCPUFA levels in plasma or red blood cell mem-
branes when fed non-supplemented formulae. Current recommendations indicate that in-
fant formulae should contain LCPUFA in quantities comparable to breastmilk.(2) 
Several studies demonstrated that breastfed infants have a better cognitive outcome 
than infants fed formula.(3) However, differences between breastfed and formula fed chil-
dren can not only be attributed to nutrition, but are also explained by related factors, such 
as higher maternal IQ(3) and genotype.(4) 
Interestingly, Batstra et al.(5) reported that breastfeeding abolished the negative ef-
fect of exposure to maternal smoking during pregnancy on cognitive outcome at school 
age. Exposure to maternal smoking during pregnancy is known to be associated with a neg-
ative effect on the child’s behavioural and cognitive outcome.(6) Possibly this negative effect 
is mediated by an adverse effect of maternal smoking on the infant’s capacity to synthesize 
AA and DHA,(7) which in turn could lead to a subclinical LCPUFA deficiency at birth.
Systematic reviews concluded that LCPUFA supplementation is associated with im-
proved developmental outcome during early infancy. However, no benefits of supplemen-
tation were found when follow-up took place between 6 and 24 months of age.(8) Studies 
reporting cognitive and behavioural follow-up at school age are lacking.
The current study is part of the Groningen LCPUFA study, a randomized controlled 
trial on the effect of formula supplementation with LCPUFA during the first two postnatal 
months in healthy term infants. Previously the study reported that LCPUFA supplementa-
tion and breastfeeding were associated with a developmental advantage at 3 months but 
not at 18 months.(9,10) Recently the participants of the study were re-assessed at 9. The re-
assessment indicated that LCPUFA supplementation did not affect the presence or absence 
of minor neurological dysfunction and that breastfed children showed fine manipulative 
disability less often than formula fed infants.(11) In the present report we focus on cogni-
tive abilities and behaviour. 
Studies in infant baboons showed that LCPUFA are incorporated in the brain’s gray 
matter, in particular the cerebral cortex and the basal ganglia.(12) Consequently, it is like-
ly that functions such as motor learning, intelligence, executive functions, attention, and 
memory which heavily depend on distributed neuronal networks including cortical areas 
and basal ganglia, will benefit most.(13) Therefore we hypothesize that LCPUFA supple-
mented children will score higher than children fed control formula on tests of intelligence, 
executive function, attention and learning and memory. Also, we hypothesize that breast-
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fed children perform better on cognitive tests than formula fed children. More specific, we 
expect that a potential beneficial effect of LCPUFA is reflected especially in improved intel-
ligence, executive function, attention, learning and memory, and less in an effect on lan-
guage ability. Both cognition and behaviour are the result of a continuous interaction be-
tween genetic background and environment. However, behaviour is more strongly affected 
by environmental conditions such as family functioning than cognition.(14,15) Therefore 




The study is an extension of a double-blind randomized controlled trial investigating the 
effect of LCPUFA-supplementation on development of healthy term infants. The study was 
designed to detect a  difference of  7.5 on the mental developmental index of  the Bayley 
test at 18 months between the LF and CF groups. Fifty-seven children had to be included 
in each group (for details see (9)). In parallel a group of breast-fed healthy term infants 
was enrolled which served as a reference group. Pregnant women were recruited between 
1997 and 1999. Mothers of 312 infants chose to bottle feed and 160 opted for breastfeed-
ing. The infants receiving formula were randomized into standard formula group (con-
trol formula, CF, n = 169) or LCPUFA supplemented formula group (LF, n = 145) by means 
of a single central computerized randomization that used a block design (blocks of 6 de-
livered in batches of 78). Standard formula was Nutrilon Premium®. For the supplemented 
formula, the lipid fraction of Nutrilon Premium® was enriched with 0.45% (by wt) AA and 
0.30% (by wt) DHA. Supplementation duration was 2 months. When breastfeeding stopped 
before 2 months, the infant received LCPUFA-supplemented formula till 2 months. Fifty 
percent of mother stopped breastfeeding when the infant aged 2 months, which conforms 
to Dutch breastfeeding practices.(16) All formula-fed (FF) infants received control formula 
between 2 and 6 months. All 472 participating infants were born at 37-42 week of gesta-
tion and were of native western European origin. Excluded were infants with a congenital 
disorder interfering with adequate daily functioning, twins, infants whose mothers did not 
have mastery of the Dutch language or who suffered from significant illnesses or disability, 
adopted and foster infants and formula fed infants who had received human milk for more 
than 5 days. 
Children assessed at 18 months (436, 92% of the original 459) were invited at 9 
years. Parents and examiners were blind to type of formula-feeding the infant had re-
ceived. The examiners were also blind to formula versus breast status. 
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3.3.2 Procedures 
The assessment at  9 consisted of  intelligence testing, evaluation of  cognitive functions, 
neurological evaluation in  terms of  minor neurological dysfunction, behavioural evalu-
ation, blood pressure measurements and anthropometrics. In the current report intelli-
gence, cognition and behaviour are addressed. Intelligence was assessed using the WASI 
– Wechsler Abbreviated Scale of Intelligence.(17) This resulted in a Full IQ (FIQ) score, 
made up of a Verbal IQ (VIQ) score and a Performance IQ (PIQ) score. The WASI is a valid 
screening instrument.(18)
Cognitive performance was assessed with the NEPSY, Tea-Ch and Children’s Mem-
ory Scale. The NEPSY(19) is designed to assess neuropsychological functioning in 3 to 12 
year old children. Three NEPSY-domains were evaluated: 1) Attention and Executive Func-
tions (Tower test – further denoted as executive function), 2) Memory and Learning ability 
(Memory for Names, Memory for Faces and Narrative Memory) and 3) Language ability 
(Comprehension of instructions and Speeded naming). The latter domain was included to 
serve as a control domain in which we did not expect a nutritional effect. The Tea-Ch – Test 
of Everyday Attention for Children – is a standardized and valid test for the assessment 
of attention in children aged 6 to 16 years.(20) All domains were assessed, however using 
a reduced set of subtests: 1) Selective attention (using the Sky Search test), 2) Sustained at-
tention (using the Score test and Sky Search DT test) and 3) Attentional control/switching 
(using the Creature Counting test and Opposite Worlds test; note that switch attention is 
also known as divided attention). Also verbal memory was assessed with the word Pair 
subtask of the Children’s Memory Scale. For all tests the original norms were used as Dutch 
norms were not available. 
Behaviour was evaluated by means of parental and teacher’s questionnaires, i.e., the 
Dutch versions of the Children’s Behavioural Check List (CBCL)(21) and the Teacher Report 
Form (TRF).(21) The reliability and validity of CBCL and TRF are well established.(21,22)
Data on pre- and perinatal conditions were collected during enrolment using the 
Obstetrical Optimality Score (OOS).(23) At the 18 months assessment maternal verbal 
intelligence (IQ) was estimated with an abbreviated version of the Wechsler Adult Intel-
ligence Scale (WAIS III), using the subtests information and vocabulary.(24) At the 9 year 
follow-up, information was collected on parental education and profession, the child’s 
medical history, nutritional habits and family composition. 
The neuropsychological assessments were carried out by  two psychologists, de-
pending on the wish of the parent either at the hospital or at the home of the children. The 
study was conducted according to the guidelines laid down in the Declaration of Helsinki 
all procedures involving human subjects were approved by  the Ethics Committee of  the 
Groningen University Hospital. Written informed consent was obtained from all partici-
pants. The trial is registered under ISRCTN52788665.
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3.3.3 Statistical analysis 
The purpose of the statistical analyses was to compare the two randomized formula feeding 
groups and the breastfeeding group with respect to ten cognitive outcome variables and 
secondarily to behavioural variables while adjusting for possible confounders. As IQ and 
specific cognitive variables appeared to be normally distributed we used multiple linear re-
gression analysis for these 10 outcomes. The behavioural outcomes, that were not normally 
distributed, were dichotomized into normal versus borderline/clinical according to Dutch 
norms,(21) and analysed by logistic regression analysis. 
We included the following variables as potential confounders: gender, maternal 
estimated verbal IQ, maternal level of education (1 = low, 2 = medium, 3 = high), duration 
of breast feeding and pre-pregnancy maternal body mass index (BMI). Special attention 
was paid to smoking during pregnancy. In line with other developmental studies, smoking 
was dichotomized into no/minimal smoking defined as <5 cigarettes per day and evident 
smoking defined as ≥5 cigarettes per day.(7) In the regression analysis we also explored the 
existence of  interactions between the feeding type and the potential confounders whose 
main effects were significant at  5% level. The results are presented as either differences 
between adjusted means of the three feeding groups or as adjusted odds ratios, with the 
corresponding 95%-confidence intervals (CI) and P-values.
The CI’s and P-values are not corrected for multiple testing. To (Bonferroni-) cor-
rect the three pairwise comparisons between feeding groups the P-values could be multi-
plied by three. This is however not appropriate if one is primarily interested in comparing 
the two randomized formula groups. To correct for the multiplicity of tests for interac-
tions is more complicated. As a rough solution we have chosen to test them at 1% level. 
As the analysis involved 10 outcome variables, a Bonferroni correction for multiplicity 
can be contemplated as well. It is up to the reader to decide for which group of cognitive 
tests this should be applied. The analyses were performed using SPSS 14.0 for Windows 
(SPSS, INC, Chicago IL).
3.4 Results
Of the 436 eligible children 341 participated (72% of the original study group n = 474, Fig-
ure 1) Obstetric and sociodemographic characteristics are described in Table 1. In general, 
obstetric and social characteristics of the children who were and who were not assessed at 9 
years were comparable, including maternal smoking during pregnancy. Yet the children 
who took part in  the follow-up at  9 years showed a  less optimal neuromotor condition 
in early infancy. Also, in the LF group a selective attrition of boys (LF: 36 male 18 female, 
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CF: 27 male 19 female, BF: 15 male 18 female; p = 0.003) and of children with a lower men-
tal developmental index (MDI) at 18 months (MDI of   children not assessed at 9 years: 
LF = 112, CF = 118, BF = 121; p = 0.007) had occurred. 
None of the test results were affected by current consumption of fish or the duration 
of exclusive breastfeeding. 
474 healthy infants enrolled at birth
Control formula for 2 
months 
N=169














6 lost to follow -up*
10 lost to follow -up*
12 lost to follow -up*
20 lost to follow -up
7 withdrew consent
35 lost to follow -up
9 withdrew consent
28 lost to follow -up
6 withdrew consent
N=84N=113 N=123
11 excluded from 
current analysis due 
to missing data
Analysis
Figure 1. Flow diagram of children enrolled in the study and followed up until 9 years of age.
* for more detailed information see (10)
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Table 1. Obstetric and social characteristics of the three groups assessed at 9 years 
Variable CF group (n = 123) LF group (n = 91) BF group (n = 127)
Gender, boys/girls 71 / 52 42 / 49 64 / 63
Maternal obesity before pregnancy 
(BMI≥25), % 60% 47% 39%
Weight gain during pregnancy, 
median (range) 13 (0–46) 13 (0–26) 14 (0–31) 
Presence of maternal smoking >5 
cig/day during pregnancy, %# 23% 19% 10%
Presence of maternal hypertension 
during pregnancy, % 17% 12% 9%
Birth weight (g), mean (SD) 3518 (473) 3527 (498) 3588 (436)
Apgar score after 3 minutes, median 
(range) 10 (7–10) 10 (7–10) 10 (5–10)
OOS, median (range) 59 (46–67) 59 (50–67) 60 (43–69)
Maternal education *
- high a, % 
- medium b, %










a University education or vocational college
b College graduate or junior vocational college
c No education or primary education
*significant difference between all groups p = 0.001
OOS = Obstetrical Optimality Score
3.4.1 Nutrition and intelligence 
Multiple regression analysis of FIQ (Table 2) revealed an interaction between infant nutri-
tion and smoking during pregnancy. In children of mothers who had smoked during preg-
nancy the mean FIQ of CF children was lower than that of  BF children (Table 2a, Figure 
2). Mean FIQ of LF children prenatally exposed to maternal smoking did not differ from 
that of the CF or BF children. In the group children whose mothers had not smoked during 
pregnancy nutrition did not affect FIQ. 
Verbal IQ and performance IQ showed different relationships with infant nutri-
tion. Multiple regression analysis of VIQ (Table 2a) revealed an interaction between nu-
tritional group and smoking during pregnancy. In the children prenatally exposed to ma-
ternal smoking mean VIQ of LF children was significantly higher than that of CF children 
(p = 0.007; figure 3) and the mean VIQ of  BF children did not differ significantly from 
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that of the other two groups. In the group of children whose mother did not smoke dur-
ing pregnancy nutrition did not affect VIQ. The multiple regression analysis indicated that 
nutrition was not associated with PIQ (data not shown).
Table 2a. Analysis of factors contributing to Full IQ and Verbal IQ.
Full IQ Verbal IQ
Effect 95% CI P-value Effect 95% CI P-value
Type of feeding within 
smoking during pregnancy
Non-Smoking LF vs CF -3.71 -7.47 , 0.05 0.053 -3.65 -7.16 , -0.14 0.028
BF vs CF  0.713 -2.96 , 4.38 0.703 0.54 -2.90 , 3.97 0.213
BF vs LF  4.43 0.546 , 8.3 0.026 4.19 0.56 , 7.83 0.020
Smoking LF vs CF  7.19 -0.60 , 14.97 0.070 9.94 2.69 , 17.19 0.007
BF vs CF  12.21 3.68 , 20.73 0.005 10.02 2.08 , 17.96 0.014
BF vs LF 5.02 -4.38 ;14.42 0.294 0.085 -8.67 , 8.84 0.980
n = 301; FIQ R2 = 0.29; VIQ R2 = 0.28
BF / LF / CF: Breastfed / LCPUFA supplemented / Control group
CI: Confidence Interval 
Adjusted for: gender, maternal verbal IQ, maternal education and maternal BMI before pregnancy. 
3.4.2 Nutrition and executive function and attention
In the domain of executive function and attention no interaction between smoking dur-
ing pregnancy and nutrition was found. The multivariate analysis showed a  lower mean 
performance of  the LF group for executive function compared to the CF group, but no 
differences between the LF and BF groups (Table 2b). Infant nutrition was not associated 
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Figure 3. Verbal IQ: effect of early nutrition and prenatal exposure to maternal smoking Bold 
horizontal lines indicate median values (values provided); boxes represent interquartile ranges 
(IQRs); Vertical lines represent 1.5 IQR and small circles reflect outliers. * p < 0.01 when ad-
justed for confounders
Figure 2. Full IQ: effect of early nutrition and prenatal exposure to maternal smoking Bold 
horizontal lines indicate median values (values provided); boxes represent interquartile ranges 
(IQRs); Vertical lines represent 1.5 IQR and small circles reflect outliers. * p < 0.01 when ad-











Not xposed to smoking
*
 Effects of long-chain polyunsaturated fatty acids supplementation of infant formula 
on cognition and behaviour at 9 years of age
57
Table 2b. Analysis of factors contributing to the NEPSY subscale executive function
Type of feeding 
Executive function
Effect 95% CI P-value
LF vs CF (ref) -1.25 -2.01 ; -.49 0.001
BF vs CF -.243 -1.00 ; .52 0.529
Bf vs LF 1.01 0.21 ; 1.8 0.014
n = 299; executive function R2 = 0.059, intercept 10.45 
CF / LF / BF: Control / LCPUFA supplemented / Breastfed group
CI: Confidence Interval
Adjusted for gender, maternal verbal IQ, maternal education, maternal smoking during pregnancy and 
maternal BMI before pregnancy. 
3.4.3 Nutrition and learning and memory 
For learning and memory multiple regression analysis revealed an interaction between in-
fant nutrition and maternal smoking during pregnancy. In children of smoking mothers 
the LF children scored significantly better than the CF children whereas mean performance 
of BF children did not differ significantly from that of CF and LF children (Figure 4). In the 
group of children whose mother did not smoke during pregnancy nutrition did not affect 
learning and memory.
Also for verbal memory an interaction between maternal smoking and infant nutri-
tion was found. In children whose mother smoked verbal memory was not affected by infant 
nutrition (Table 2c, figure 5). However, in children not exposed to maternal smoking LF chil-
dren had mean lower verbal memory scores than CF children whereas no evidence of a dif-
ference was found between BF children and either of the two formula groups (Table 2c). 
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Table 2c. Analysis of factors contributing to learning and memory and verbal memory 
Contributing 
factors:
Learning and memory Verbal memory
Effect 95% CI P-value Effect 95% CI P-value
Type of feeding within smoking 
during pregnancy
Non-Smoking LF vs CF -0.617 -1.28 ; 0.04 0.066 -1.49 -2.48 ; -0.50 0.003
BF vs CF 0.25 -0.38 ; 0.88 0.438 -0.92 -1.88 ; 0.04 0.059
BF vs LF 0.867 0.19 ; 1.54 0.012 0.571 -0.44 ; 1.58 0.270
Smoking LF vs CF 1.883 0.55 ; 3.22 0.006 1.17 -0.87 ; 3.21 0.260
BF vs CF 1.64 0.16 ; 3.13 0.030 1.37 -0.88 ; 3.62 0.230
BF vs LF -0.24 -1.87 ; 1.39 0.770 0.206 -2.2 ; 2.6 0.870
n = 330; Learning and memory R2 = 0.17; verbal memory R2 = 0.077.
BF / LF / CF: Breastfed / LCPUFA supplemented / Control group
CI: Confidence Interval
Adjusted for gender, maternal verbal IQ, maternal education and maternal BMI before pregnancy.
Figure 4. Learning and Memory: effect of early nutrition and prenatal exposure to maternal 
smoking Bold horizontal lines indicate median values (values provided); boxes represent in-
terquartile ranges (IQRs); Vertical lines represent 1.5 IQR and small circles reflect outliers 
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3.4.5 Nutrition and language 
Multivariable analyses indicated that scores on the language subscale of the NEPSY were 
not affected by infant nutrition (data not shown).
3.4.6 Nutrition and behaviour at home and at school 
No evidence of  a  difference between the two formula groups nor between the formula 
groups and the BF group was found for the behavioural outcomes (data not shown). 
3.5 Discussion 
The present study indicates that in  healthy term infants postnatal supplementation with 
LCPUFA for two months is not associated with a consistent beneficial effect on cognitive func-
tion at school age. Nevertheless, some effects were found, which were partially dependent on 
maternal smoking status during pregnancy. In children prenatally exposed to smoking LCP-
UFA supplementation was associated with positive effects on VIQ and learning and memory. 
In children whose mother had not smoked during pregnancy LCPUFA supplementation was 
associated with a negative effect on verbal memory. Also, LCPUFA supplementation was as-
Figure 5. Verbal Memory: effect of early nutrition and prenatal exposure to maternal smoking 
Bold horizontal lines indicate median values (values provided); boxes represent interquartile 






























sociated with a slightly lower mean performance on executive function. The domains affected 
by early nutritional modification involving LCPUFA, i.e., executive function and learning and 
memory and not language ability, were in line with our expectations. The direction in which 
outcome was affected by LCPUFA differed however from our expectations. The study con-
firmed the association between breastfeeding and better cognitive abilities for IQ.
A major limitation of the study is the 28% attrition. In longitudinal studies of this 
type a loss to follow-up is well-known and often inevitable,(25) attrition of less than 30% 
in 9 years may be viewed as relatively favourable. In addition two forms of selective attrition 
occurred: 1) a selective loss of children with optimal development in early infancy and 2) 
a selective loss of boys and children with a worse cognitive development at 18 months in the 
LF group. This means that from a developmental point of view the children studied may be 
considered as a slightly negative selection, and the LF children included in the follow-up 
a positive selection. The latter may imply that the minor negative effect of LCPUFA found 
in the present study might have been larger if our study had not suffered from selective 
drop-out of LF-children with a lower cognitive performance at 18 months. Attrition was 
not selective for smoking during pregnancy, the major modifier of the effect of LCPUFA 
supplementation on cognitive development. 
Strengths of the study lie in the randomized design, the accurate prenatal and peri-
natal documentation, the long term follow-up period and the inclusion of an estimated 
maternal verbal IQ. Our study is the first to report effects of LCPUFA supplementation on 
cognition and behaviour at 9. 
The effect of LCPUFA on cognitive function partially depended on the presence 
or absence of maternal smoking during pregnancy: supplemented children of non-smok-
ing mothers had lower mean scores on verbal memory than control formula fed children, 
whereas supplemented children who were exposed to prenatal smoking had higher mean 
scores on VIQ and learning and memory than control formula children. Important to real-
ize is that the negative effect of LCPUFA was relatively small (e.g. 3 points of IQ) whereas its 
positive effect in the infants exposed to prenatal smoking was about 6 points of IQ. The lat-
ter is close to half the standard deviation of 15. Such small differences may not be relevant 
for an individual but may be considered relevant on population level. The data confirmed 
that in infants receiving non-supplemented formula prenatal exposure to smoking is asso-
ciated with a reduction of FIQ of approximately 10 points.(26) Previously Agostoni et al.(7) 
reported that smoking during pregnancy is associated with a diminished maternal capacity 
to synthesize AA and DHA. Our data suggest that a relative LCPUFA deficiency induced 
by maternal smoking during pregnancy may be compensated by the provision of LCPUFA 
after birth. This corresponds to the previously mentioned finding of Batstra et al.(5) who 
found a similar effect of breastfeeding. 
Contrary to our expectations and to the assumptions in the literature(27) we also 
found minor negative effects of LCPUFA supplementation. A negative effect of LCPUFA 
supplementation was also reported by Van Goor et al,(28) who studied the effect of LCPU-
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FA supplementation during pregnancy and lactation on neurological outcome in infancy. 
Additionally, the individual patient meta-analysis of Beyerlein et al(29) that did not find 
a  statistically significant effect of  postnatal LCPUFA supplementation on development, 
showed a  trend towards a  negative effect of  LCPUFA on cognitive outcome. The data 
of these studies and the present data underscore that our understanding of fatty acid bal-
ances and their effect on the developing brain is limited.
Interestingly, the negative and positive effects associated with LCPUFA supplemen-
tation were found in  the cognitive domains mediated by neural structures known to be 
sensitive to LCPUFA status.(12) The findings emphasize our limited understanding of the 
effect of LCPUFA on the developing human brain. Critical factors may be the timing of the 
nutritional intervention, and the balance between the various fatty acids that in the current 
make-up may not have optimally met the needs of the developing brain.(30,31) 
Our study confirmed that breastfeeding is associated with improved cognitive abili-
ties.(3) The data suggest that minor part of this association may be attributed to LCPU-
FA, as breastfeeding in children whose mother smoked during pregnancy was associated 
with a higher mean IQ in a similar way as LCPUFA-supplementation was associated with 
a higher mean IQ. In children not exposed to prenatal smoking (the majority of children), 
this association did not seem to play a major role. This fits with the notion that major part 
of the positive association between breastfeeding and cognitive abilities can be attributed to 
shared genome and maternal behaviour associated with breastfeeding practice.(3) 
The present study warrants three conclusions. First, in healthy term infants no con-
sistent beneficial effect of postnatal LCPUFA supplementation on cognitive function was 
found. Second, the data suggest a beneficial role of LCPUFA in the subgroup of children 
exposed to maternal smoking during pregnancy. Third, only minor part of the association 
between breastfeeding and higher IQ is mediated by LCPUFA.
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4.1 Abstract
Conflicting evidence exists on the effect of  long-chain polyunsaturat-
ed fatty acid (LCPUFA) formula supplementation on cardiovascular 
health in term infants. It is known that LCPUFA supplementation does 
not affect infant growth, but long term outcome data are not available. 
The current study investigates whether two months LCPUFA formula 
supplementation affects cardiovascular and anthropometric develop-
ment at 9 years. A prospective, double-blind, randomized control study 
was performed in  healthy term infants: a  standard formula control 
group (CF, n = 169) and a LCPUFA-supplemented group (LF, n = 145). 
A breastfed group (BF; n = 159) served as reference. At age 9, systolic 
and diastolic blood pressure, heart rate, head circumference, weight and 
height were measured. Univariate and multivariate analyses were per-
formed. 63 to 79% of children were assessed. None of the cardiovascular 
or anthropometric measurements differed between the formula groups. 
Breastfed children had a marginally lower heart rate than formula fed 
children, in particular compared to children fed control formula. Blood 
pressure and parameters of growth including body mass index of breast 
and formula fed children did not differ. In conclusion, the study sug-
gests that short term LCPUFA supplementation does not influence car-
diovascular and anthropometric development at 9 years. 
4.2 Abbreviations
AA:  Arachidonic Acid
BF:  Breastfed
CF:  Control Formula
DHA:  Docosahexaenoic Acid
LCPUFA:  Long-Chain Poly Unsaturated Fatty Acids
LF:  LCPUFA Supplemented Formula
OOS:  Obstetric Optimality Score
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4.3 Introduction
The notion that breastfeeding has consistently been associated with a modest beneficial ef-
fect on blood pressure in later life is relevant for public health(1,2). The underlying mecha-
nisms of the association are not clear. Long-Chain Polyunsaturated Fatty Acids (LCPUFA) 
may be candidates. 
Until recently LCPUFA were not present in standard formula. Formula only con-
tained the precursor essential fatty acids, alpha-linolenic acid (ALA,18:3n-3) and linoleic 
acid (LA, 18:2n-6). As young infants have a limited capacity to synthesize docosahexaenoic 
acid (DHA) and arachidonic acid (AA) from these precursors (3), LCPUFA levels in plas-
ma or red blood cell membrane gradually decline in infants fed non supplemented formu-
lae indicating a relative LCPUFA deficiency. Based on the advantageous effect of LCPUFA 
supplementation on neurodevelopment assessed at young age, it is advised that infant for-
mulae should contain LCPUFA in quantities comparable to breastmilk(4). Consequently, 
most of the formulas currently on the market contain LCPUFA. However, there is still an 
ongoing debate concerning the long term consequences of dietary LCPUFA, including the 
effect on blood pressure regulation.
Studies on the effects of early LCPUFA supplementation on cardiovascular indices 
in humans, such as blood pressure and heart rate, are limited in number and heterogeneous 
in methodological quality (Table 1, 5–10). They also differ in the duration of supplementa-
tion, fatty acid dosage and lipid composition. Two studies on early postnatal supplementa-
tion with LCPUFA (5,6) and one in late infancy (7) reported beneficial effects of LCPUFA 
on blood pressure and heart rate in later life. Two other studies however found no effect 
of LCPUFA supplementation in early life (8,9) and one study even found a negative effect 
in school age boys(10). 
Two recent meta-analyses indicated that early postnatal LCPUFA supplementation 
in term infants does not affect growth measures such as head circumference, weight, length 
and the resulting body mass index (BMI) until the age of 18 months(11,12). Breastfeeding 
on the other hand, is associated with a small but consistent reduction in obesity risk in later 
childhood (13). However, it is debated whether the effect is mediated by  the nutritional 
contents of  human milk or by  associated factors, such as less maternal smoking during 
pregnancy and a maternal BMI < 25 (14).
The current study is part of the Groningen LCPUFA study, a randomized controlled 
trial on the effect of supplementation of formula with LCPUFA during the first two postna-
tal months in healthy term infants. The focus of the study is neurodevelopmental outcome, 
but also some other indicators of child health are evaluated. Previously the study reported 
that LCPUFA supplementation and breastfeeding were not associated with growth advan-
tages at 18 months(12). Recently the participants of the study were re-assessed at 9 years. 
Here we report on cardiovascular health expressed as blood pressure and heart rate, and 
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The primary aim of the current paper is to explore whether the short term postnatal 
LCPUFA intervention was associated with blood pressure, heart rate and anthropometric 
development at  9 years. Additionally we explored whether breastfeeding was associated 
with a beneficial effect on blood pressure, heart rate and anthropometric development. 
4.4 Methods
4.4.1 Subjects
The study is part of  a  double-blind randomized controlled trial investigating the effect 
of LCPUFA-supplementation on the development of healthy term infants (the Groningen 
LCPUFA study). Details on the study design, including exact diet composition, have been 
described previously (15). Between 1997 and 1999, expecting mothers were recruited dur-
ing pregnancy checkup visits at  the University and Martini Hospitals in Groningen and 
at midwife clinics in and near Groningen. Final enrollment occurred in the neonatal period. 
All infants were born at 37–42 wk of gestation. Mothers of 314 infants chose to bottle feed 
their child and 160 opted for breastfeeding. The infants receiving formula were randomized 
into a standard formula group (control formula, CF, n = 169) and a LCPUFA supplemented 
formula group (LF, n = 145). Standard formula consisted of Nutrilon Premium®. For the 
supplemented formula, the lipid fraction of Nutrilon Premium® was enriched with 0.45% 
(by wt) AA and 0.30% (by wt) DHA. The LCPUFA were provided as mix of phospholipids 
(15%) and triglycerides (85%) to mimic the composition of breastmilk. Supplementation 
lasted till the end of the second postnatal months. In case breastfeeding stopped prior to 2 
months, the infant received LCPUFA-supplemented formula till the full age of 2 months. 
All formula-fed infants received control formula from two completed months until the 
age of 6 months. All 436 children (92% of the original groups) assessed at 18 months were 
eligible for re-examination at 9 years. At the 9 year follow-up, both parents and examiners 
were unaware of the type of formula-feeding the infant had received. The examiners were 
also blind to formula versus breast status. 
4.4.2 Protocol and measurements
In the current follow-up the children and their parents were contacted and, depending on 
the wish of the participants, assessments were carried out either at the hospital or at home. 
Three hundred and forty one children agreed to participate: 91 in  the LF-group (63%), 
123  in  the CF-group (73%) and 127 in  the breastfed group (BF-group) (79%; Figure 1). 
During the study type of  feeding was assessed prospectively by daily diaries filled in by 
the mothers until the infant was 8 months. Duration of breastfeeding varied from 1 to 56 
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weeks; 50% of mothers exclusively breastfed beyond 2 months. The assessments of cardio-
vascular parameters and anthropometrics were part of a more extensive evaluation focus-
ing on neurodevelopmental outcome, see also(16). 
Blood pressure and heart rate were measured immediately following a 15 minute 
rest period, measurement took place on the left arm with the child sitting on a chair and the 
arm resting on a table. An automated blood pressure monitor was used (Datascope Accu-
torr plus, Datascope corporation, Mahwah, USA) with a small adult cuff (10.6–23.9 cm size 
bladder; measuring with a precision of micrometers Hg). This procedure was performed 
twice during the assessment with an interval of an hour. In all children heart rate, systolic 
and diastolic blood pressure were recorded as the mean of the two readings.
Weight was measured using a calibrated radwag scale (Radwag, Radom, Poland; 
which measured with a  precision of  500 milligrammes) and body length using a  Seca 
stabilometer (Seca Deutschland, Hamburg, Germany; which measured with a  precision 
of millimeters). BMI was determined using international standards, taking gender and age 
into account (17). Occipitofrontal head circumference was assessed using a nonstretchable 
‘lasso’ tape which measured with a precision of millimeters.
474 healthy infants enrolled at birth
Control formula for 2 
months 
N=169














6 lost to follow -up*
10 lost to follow -up*
12 lost to follow -up*
20 lost to follow -up
7 withdrew consent
35 lost to follow -up
9 withdrew consent
28 lost to follow -up
6 withdrew consent
N=84N=113 N=123
11 excluded from 
current analysis due 
to missing data
Analysis
Figure 1. Flow diagram of children enrolled in the study and followed up until 9 y of age.
* for more detailed information see (21)
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Data on pre- and perinatal conditions had been collected during enrollment with 
the help of the Obstetric Optimality Score (OOS).The OOS describes the obstetric condi-
tions ranging from the parents’ socio-economic status to the infant’s condition immediately 
after birth (18). Anthropometrics had been recorded at birth and at 3 and 18 months (12). 
At the 9 year follow-up information was collected on parental education and profession, 
the child’s medical history, nutritional habits and family composition.
This study was conducted according to the guidelines laid down in the Declaration 
of Helsinki and all procedures involving human subjects were approved by the Ethics Com-
mittee of the Groningen University Hospital. Written informed consent was obtained from 
all subjects. The trial is registered under ISRCTN52788665.
4.4.3 Data analysis 
The study was originally designed to detect a difference of 7.5 on the mental developmental 
index of the Bayley test of infant development at the age of 18 months between the LF and 
CF groups (assuming SD = 15, power 80% at 5% significance level). Accordingly, at least 57 
children had to be included in each formula group. 
Statistical analysis focused on differences between the two randomized groups, 
in addition differences between the formula groups and the breastfed group were analysed. 
The anthropometric and blood pressure data, apart from the children’s BMI, were normal-
ly distributed. We used independent samples t-tests for crude comparison of the feeding 
groups and linear regression analysis for comparison adjusted for potential confounders. 
The children’s BMI was dichotomized into normal (< = 25) / overweight (>25), chi-square 
tests were used for crude comparisons between the feeding groups and logistic regression 
analyses for comparisons adjusted for potential confounders. 
Factors included into the multivariate analyses were variables associated with out-
come at p < 0.20: gender, maternal level of education (1 = low, 2 = medium, 3 = high), smok-
ing during pregnancy (yes or no), duration of  the second stage of delivery, Apgar score 
at one and three minutes, birthweight, OOS and pre-pregnancy maternal body mass index 
(BMI). In line with other developmental studies, smoking was dichotomized into no/mini-
mal smoking defined as <5 cigarettes per day and evident smoking defined as ≥ 5 cigarettes 
per day(19). Specific attention was paid to duration of exclusive breastfeeding as poten-
tial confounder. Anthropometric parameters at 3 and 18 months were not included in the 
multivariate analyses as they were not regarded as confounders but as outcome variables. 
A p-value of 0.05 or less was considered as statistically significant. Statistical analyses were 




In general, obstetric and social characteristics of children assessed at 9 years were compara-
ble to those not participating in the follow-up at 9 years (Table 2 and Table 3). Nonetheless 
some selective attrition was present, the children who took part in the follow-up showed 
a less optimal neuromotor condition at 3 months (p = 0.003). Also, part of the attrition was 
group specific, more boys in the LF group did not partake (35 boys and 17 girls) compared 
to both the BF group (15 boys and 17 girls) and the CF group (24 boys and 17 girls). Ad-
ditionally, in  the LF group more children with a  lower mental development index at 18 
months were lost to attrition (p = 0.007; see (16)). Attrition was, however not selective for 
parameters of growth at birth and during infancy (Table 3).
Table 2. Obstetrical and social characteristics of the three groups assessed at 9 years 
CF group (n=123) LF group (n=91) BF group (n=127)
Gender, boys/girls 71 / 52 42 / 49 64 / 63
Maternal BMI, median (range) 24.7 (17.7 – 40.9)
23.7 
(18.2 – 35.9) 22.6 (17.2 – 38.2)
Weight gain in kilograms during pregnancy, 
median (range) § 13 (0 – 46) 13 (0 – 26) 14 (0 – 31)
Presence of maternal smoking during 
pregnancy, n (%)§ 28 (23%) 17 (19%) 13 (10%)
Presence of maternal hypertension during 
pregnancy, n (%) 21 (17%) 11 (12%) 11 (9%)
Birth weight (g), mean (SD) 3518 (473) 3527 (498) 3588 (436)
Apgar score after 3 minutes, median (range) 10 (7 – 10) 10 (7 – 10) 10 (5 – 10)
OOS, median (range) 59 (46 – 67) 59 (50 – 67) 60 (43-69)
Maternal education *
- high‖, n (%) 
- medium†, n (%)










‖ University education or vocational college
† College graduate or junior vocational college
‡ No education or primary education
* significant difference between all nutritional groups, found both in the groups lost to attrition and the 
groups assessed at 9: p<0.01
§significant difference between BF and FF in children assessed at 9: p<0.05 
FF: Formula Fed
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Table 3. Growth, height and head circumference in the three nutritional groups a) weight (kg), b) 
height (cm), c) head circumference (cm). 
CF LF BF 
n Mean (SD) n Mean (SD) n Mean (SD)
Weight at Birth 118 3.518 (0.473) 88 3.527 (0.50) 127 3.588 (0.436)
Weight 3 mo 95 6.306 (0.744) 80 6.323 (0.687) 120 6.253 (0.764)
Weight 18 mo 71 12.040 (1.40) 66 11.910 (1.40)  80 12.020 (1.430)
Weight 9 yr 116 34.0 (7.0) 85 33.70 (5.40) 124  33.10 (6.50)
Height at Birth 62  51.0 (2.2) 40  51.0 (2.2)  58  51.0 (2.0)
Height 3 mo 94  63.1 (2.6) 80  63.1 (2.6) 120  62.6 (2.6)
Height 18 mo 121 85.7 (3.5) 90 85.4 (3.7) 126  85.4 (3.8)
Height 9 yr 123 139.8 (5.3) 90 139.8 (5.9) 126 139.8 (6.2)
Head circumference Birth 57 35.0 (1.6) 38 34.6 (1.4)  43 34.9 (1.5)
Head circumference 3 mo 96 41.2 (1.5) 80 40.9 (1.3) 119 40.8 (1.3)
Head circumference 18 mo 119 48.4 (1.6) 90 48.1 (1.4) 125 48.4 (1.5)
Head circumference 9 yr 122 53.5 (1.7) 88 53.2 (1.6) 127 53.7 (1.6)
Systolic and diastolic blood pressure of LF-children did not differ from that of CF-
children. Likewise, blood pressures of breastfed children did not differ from that of those 




Table 4. Blood pressure, heart rate and anthropometrics at 9 years
CF group LF group BF group
M (SD) n M (SD) n M (SD) N
Systolic BP 
(mm Hg) 104.59 (7.9) 117 104.53 (9.0) 90 105.17 (7.8) 124
Diastolic BP 
(mm Hg) 63.78 (7.6) 117 62.27 (8.5) 90 63.77 (8.0) 124
Heart rate (beats/minute) 78.72 (10.3) 113 78.20 (9.2) 88 76.19 (9.6) 124
Head circumference
(cm) 53.40 (1.6) 122 53.17 (1.6) 88 53.70 (1.6) 127
BMI 
(% normal) 72% 116 76% 85 79% 123
BP= Blood pressure
M= Mean
BMI was determined using international standards by Cole (17) taking age and gender into account
Heart rate of  LF-children did not differ from that of  CF-children (Table 4), but 
heart rate of the BF group was slightly lower than that of the CF group (p = 0.04; effectsize 
0.914 ). Multivariate analyses confirmed the marginal difference (p = 0.049, 95%CI:-58.09 
to -0.009; Table 5).
Weight, height, BMI and head circumference were similar in the three groups (Ta-
ble 3). Multivariate analyses confirmed the lack of difference between groups. 
Table 5. Results of linear regression analysis of factors contributing to systolic blood pressure, dia-
stolic blood pressure and heart rate 
Contributing factors:
Heartrate















Neonatal Jaundice 7.54 -0.40 ; 15.48 0.063
Heart rate: reference CF: 78.57 n=325; R2=0.24
CF group= Control group 
LF group= LCPUFA supplemented group
BF group= Breastfed group
BMI= Body Mass Index
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4.6 Discussion
Our data indicated that LCPUFA supplementation for the duration of two months in healthy 
term infants was not associated with a change in blood pressure, heart rate, weight, height, 
BMI or head circumference at  9 years. The study also revealed that children who were 
breastfed had a slightly lower heart rate at nine than children who had received formula.
A major limitation of the study is its attrition, which was 28%. However, consider-
ing the duration of the follow-up period, 9 years, this may be regarded as relatively favor-
able(20). Attrition was selective with respect to gender and cognitive development at 18 
months in  the LF group suggesting that LF-participants were a positive selection of  the 
original LF group. However attrition was not selective with respect to social class and pa-
rameters of growth at birth and during infancy (Table 3). Another limitation of the study is 
its relatively weak power. Group sizes had been determined on the basis of neurodevelop-
mental outcome at 18 months measured with the Bayley Scales of Infant Development (21). 
Post-hoc power analyses indicated that with α set at 0.05 current sample sizes allowed for 
a detection of small effect sizes (0.20) with a power of 0.80, i.e., the groups allowed for the 
detection of differences in blood pressure of 1.5 mm Hg, in heart rate of 2 beats per minute, 
in body weight of 1.5 kg and in height of 1 cm. This means that the present study was not 
able to detect more subtle effects on growth, blood pressure and heart rate. It may also be 
regarded as a limitation that our parameters of cardiovascular health and anthropometrics 
were restricted to blood pressure, heart rate, bodyweight, length, BMI and head circumfer-
ence and did not body composition, ECG and blood lipid profile. 
The strengths of the study are its randomized design, the presence of information 
on a wide range of possibly confounding variables and its assessor-blinded evaluation. 
Previous studies on the relationship between LCPUFA supplementation and blood 
pressure reported inconsistent findings: LCPUFA were associated with a positive effect on 
blood pressure, no effect or even a  negative effect. This heterogeneity presumably is the 
result of the large variation in methodological quality of the studies, ranging from the use 
of high risk populations, high selective attrition, and co-intervention with other nutrients 
and secondly from variation between the studies in dosage and duration of the intervention 
and the ages during which the intervention was applied (see Table 1). The current study 
concludes that LCPUFA supplementation of  formula for 2 months is not associated with 
blood pressure improvements of more than 1.5 mmHg and a decrease in heart rate of more 
than 2 beats per minute. This also implies that smaller effect sizes nor larger effects of longer 
periods of supplementation are not precluded. Originally our study was supposed to be one 
of a series in which also the effect of longer periods of supplementation were to be evalu-
ated. However, our short term supplementation study was the only one that was completed.
Breastfeeding on the other hand, has shown a  relatively consistent relation with 
blood pressure: it is associated with a modest decrease in blood pressure, i.e. a reduction 
of around 1.4 mm Hg in systolic blood pressure and 0.4 mm Hg in diastolic blood pressure 
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(1). These breastfeeding effects are smaller than the current study was able to detect. How-
ever we did find suggestions of a minor advantage for breastfeeding in heart rate, the other 
parameter of cardiovascular health. The minor reduction in heart rate may reflect a slight 
shift in autonomic control involving a minor decrease of sympathic dominance. This may 
be associated with a minor reduction in risk for cardiovascular diseases in adulthood (22). 
The small size of the effect is illustrated by the fact that the advantage only reached statisti-
cal significance in the comparison with control formula. Our finding of a minor beneficial 
effect of breastfeeding on cardiovascular indices is in line with other reports but somewhat 
smaller than often reported. This might be explained by the relatively short average period 
of breastfeeding, 53% of breastfed infants received a maximum of 8 weeks exclusive breast-
feeding (23), which is representative of Dutch breastfeeding habits (24). 
None of the anthropometric measures in this study were associated with early post-
natal nutrition. The lack of  effect of  postnatal LCPUFA supplementation is in  line with 
existing literature, but the lack of  difference between the breastfed and the formula fed 
groups is not. This might be explained by the limited ability to detect differences between 
the groups and to the above mentioned breastfeeding practices in the Netherlands. 
To summarize , the current study suggests that LCPUFA supplementation of for-
mula in healthy term infants for the duration of  two months does not influence cardio-
vascular and anthropometric development at the age of 9 years. Breastfeeding is found to 
have a marginal beneficial effect on cardiovascular development. The study underscores 
the need for carefully designed and well controlled studies on the effect of LCPUFA supple-
mentation on cardiovascular development.
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Chapter 5
Neonatal fatty acid status and 
neurodevelopmental outcome at 9 years





Long-Chain Poly Unsaturated Fatty Acids (LCPUFA) are important for 
prenatal brain development, previous studies assessed outcome until 
7 years. In the current study the relationship between fatty acid status 
at birth and neurodevelopment at 9 is investigated. 
An observational (cohort) study was performed as a secondary 
analysis of  data from a  prior randomized trial on effects of  postnatal 
LCPUFA including 235 children. Docosahexaenoic acid (DHA), arachi-
donic acid (AA) and trans fatty acid concentrations in umbilical vessel 
wall were determined. Neurological condition, cognition and behaviour 
were assessed at 9. Multivariate analyses were carried out to adjust for 
potential confounders. 74% of the original study group was assessed at 9 
years. Children with complex minor neurological dysfunction showed 
lower DHA values than children with better neurological condition. 
Two specific types of  neurological dysfunction were associated with 
lower venous DHA values: dysfunctional posture and tone regulation 
and dyskinesia. Neonatal AA values were not associated with neuro-
logical outcome. Neither neonatal DHA nor AA values were associated 
with cognition and behaviour at 9. Venous and arterial trans fatty acid 
values were positively associated with selective attention. We conclude 
that DHA status at birth showed a significant positive association with 
neurological condition at 9 years. AA status at birth was not associated 
with neurodevelopment at 9 years. 
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5.2 Introduction
The human nervous system increases rapidly in  size and complexity during pregnancy. 
Adequate supply of necessary nutrients such as Long-Chain Poly Unsaturated Fatty Acids 
(LCPUFA) to the fetus is essential for optimal neurodevelopment. 
Studies on the effects of docosahexaenoic acid (DHA) or fish oil supplementation 
during pregnancy on neurodevelopmental outcome provided inconsistent results (1-6). 
Observational studies on the relationship of neonatal DHA, arachidonic Acid (AA) and 
essential fatty acid (EFA) status with neurological outcome from preschool age to 7 years 
reported associations with neonatal DHA status only (7-9). Most studies using cognitive 
development as outcome measure demonstrated no associations with neonatal LCPUFA 
status (7,10,11), except for the study of Boucher et al (12). The latter study reported a sig-
nificant positive association between neonatal DHA and memory at school age. Data on the 
relation between behavioural development and LCPUFA are scarce. The only study that we 
are aware of (13) reported no associations between neonatal LCPUFA status and behaviour 
at preschool age. 
Little is known on the effects of  trans fatty acids (TFA) on human development; 
however, the negative association between TFA and LCPUFA suggests a potentially adverse 
effect (14). This hypothesis was supported by two studies that reported negative associa-
tions between TFA and neurological condition in infancy and preschool age (7,15). 
The current study is part of the Groningen LCPUFA study, a randomized controlled 
trial on the effect of  postnatal supplementation of  LCPUFA on neurodevelopment. The 
study revealed that postnatal LCPUFA supplementation was not associated with a  con-
sistent beneficial effect on neurodevelopmental outcome at 9 years (16,17). In a subgroup 
of 317 infants of the LCPUFA-cohort also fatty acid status in the umbilical cord was ana-
lyzed. The aim of the present paper is to evaluate in those healthy term infants the relation-
ship between the relative DHA, AA and TFA contents in umbilical vessel wall lipids and 
neurological, cognitive and behavioural outcome at 9 years. Primary outcome of the cur-
rent study is neurological condition in terms of minor neurological dysfunction (MND). 
Secondary outcome parameters were the so-called neurological optimality score (NOS), 
various measures of cognition and behaviour. Specific attention was paid to possible in-
teractions between neonatal fatty acid status and a) sex, as a previous study suggested that 
in particular girls may benefit from early DHA supply (18) and b) smoking during preg-
nancy, which is known to interact with postnatal LCPUFA supplementation (16).
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5.3 Subjects and Methods
5.3.1 Study population and design 
The study is an observational (cohort) study, performed as a  secondary analysis of data 
from a double-blind randomized controlled trial investigating the effect of LCPUFA-sup-
plementation on development in healthy, term infants (the Groningen LCPUFA study; for 
details see Bouwstra et al (19)). Pregnant women were recruited between February 1997 
and October 1999; from a  total of  474 mother infant pairs, 314 infants were bottle fed 
and 160 breastfed. The infants receiving formula were randomized into a standard formula 
group (control formula, CF, n = 169) and a  LCPUFA supplemented formula group (LF, 
n = 145). The standard formula was Nutrilon Premium (Milupa, Friedrichsdorf, Germany). 
For the supplemented formula, the lipid fraction of Nutrilon Premium® was enriched with 
0.45% (by wt) AA and 0.30% (by wt) DHA. The duration of supplementation was 2 months. 
In case breastfeeding stopped prior to 2 months, the infant received LCPUFA-supplement-
ed formula till the age of 2 months. All formula-fed (FF) infants received control formula 
between 2 and 6 months. 
Parents of 317 infants gave permission to obtain umbilical cord tissue (67% of the 
original population, see Figure 1).
Figure 1. Flow diagram of children enrolled in the study and followed up until 9 years of age. 
* For more detailed information see(7) 
474 healthy infants enrolled at birth
BF N=99
Umbilical cord available at birth 
Total N=317
LF N=94




27 lost to follow -up*
48 lost to follow -up
7 withdrew consent
Infants with adequate data set and umbilical cord data 
Total: N=290
Infants with adequate data set and umbilical cord data 
Total: N=223
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The umbilical cord was collected shortly after parturition. Seven to 10-cm samples 
were taken at the most proximal site of the placenta and stored in saline at 4°C for a maxi-
mum duration of 24 hour until further processing. Details on collection and processing can 
be found in Muskiet et al (20). Neurological condition was assessed at 3 and 18 months. 
All 290 children assessed at 18 months (91.5% of the original groups) were eligible for re-
examination at 9 years. At the 9 year follow-up, both parents and examiners were unaware 
of the type of formula-feeding the infant had received and of neonatal fatty acid status. The 
examiners were also blind to formula versus breast status. Depending on the wish of the 
participants, the assessment was carried out in the hospital or at home. 
This study was conducted according to the guidelines laid down in the Declaration 
of  Helsinki and all procedures involving human subjects/patients were approved by  the 
Ethics Committee of  the Groningen University Hospital. Written informed consent was 
obtained from all subjects. The trial is registered under ISRCTN52788665.
5.3.2 Analysis of the fatty acids of the umbilical vessels 
Data were expressed as percentages of weight of fatty acids with a chain length of 14-24 
carbon atoms. DHA and AA status were based on their respective levels. TFA status was 
derived from the sum of t16-1n7 + tt18-2n6 + tc18-2n6+ ct18-2n6 + t18-1n9/7 (21). 
5.3.3 Neurological assessment
Neurological condition of the children was evaluated with the examination of Touwen 
(22), which is a standardized, age specific assessment designed for the assessment of mi-
nor neurological dysfunction (MND (23)). Essential in  the diagnostics of MND is the 
presence of coherent clusters of signs, single signs do not have clinical significance, signs 
only have significance when they co-occur (cluster) with other signs within a functional 
domain. The examination is organized into eight functional domains: posture and muscle 
tone, reflexes, dyskinesia, coordination, fine manipulative ability, associated movements, 
sensory deficits and cranial nerve functioning. The examination results in a clinical clas-
sification and in a Neurological Optimality Score (NOS). The clinical classification con-
sists of  four categories: normal, simple MND, complex MND, or abnormal. A child is 
considered neurologically abnormal in the presence of a clear neurological disorder such 
as cerebral palsy. Simple MND denotes the presence of one or two domains of dysfunc-
tion and is present in about 15-20% of children. It has little clinical relevance and can 
be regarded as a  sign of  typical but non-optimal brain functioning, in other words as 
a minor neurological difference. Complex MND denotes the presence of more than two 
domains of  dysfunction and is the clinically relevant form of  MND. In an etiological 
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sense complex MND can be considered a borderline form of cerebral palsy as it is linked 
to pre- and perinatal adverse events (24). A child is classified as neurologically normal 
when no domains are scored as deviant or in case of the isolated presence of a mild dys-
function in reflex activity. 
The NOS is a quantitative expression of neurological condition. It uses the optimal-
ity concept to provide a sensitive measure of the child’s overall neurological status. For 64 
items, representing the entire neurological examination, an optimal range was identified 
(see (17,23)). The total number of items with a value within the predefined optimal range 
forms the neurological optimality score of a child. Note that there is a conceptual difference 
between normality and optimality, as the range for optimal behaviour is narrower than that 
of normal behaviour (25).
The neurological examination according to Touwen has a good intrarater, interrater 
and test-retest reliability, the kappa statistics of  the three forms of  reliability for neuro-
logical classification ranges between 0.71 and 0.83 (26). Its construct validity is reflected 
by the differential relationship for simple and complex MND with prenatal and perinatal 
adverse events: adverse conditions during early life have a weak to moderate relationship 
with simple MND and a strong correlation with complex MND (24). Also predictive valid-
ity is good; for instance the severity of MND at 9 years predicts the chance of learning and 
behavioural problems at 14 years (24,27).
5.3.4 Assessment of cognition
Assessment of cognition consisted of a battery of tests, including intelligence testing and 
the evaluation of specific cognitive functions. Intelligence was assessed using the WASI 
– Wechsler Abbreviated Scale of Intelligence (28), resulting in a Full IQ (FIQ) score. Spe-
cific cognitive performance was assessed by means of  the NEPSY, the Tea-Ch and the 
Children’s Memory Scale. The NEPSY (29) is designed to reliably assess neuropsychologi-
cal functioning in 3 to 12 year-old children in a maximum of five domains. To prevent 
possible overlap with other parts of the assessment battery, testing was limited to a rep-
resentative selection of tests in the following three domains: 1. Attention and Executive 
Functions, 2. Memory and Learning Ability and 3. Language Ability. The Tea-Ch – Test 
of Everyday Attention for Children is a  standardized and valid test for the assessment 
of attention in children aged 6 to16 years (30). All three domains were assessed: 1. Selec-
tive Attention 2. Sustained Attention and 3. Attentional Control/Switching. In addition, 
verbal memory was assessed by the Word Pair subtask of the Children’s Memory Scale. 
For WASI, NEPSY, Tea-Ch and the Children’s Memory Scale the original norms were 
used as no Dutch norms were available.
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5.3.5 Assessment of behaviour
Behaviour was evaluated by  means of  parental and teacher’s questionnaires, i.e., the Dutch 
versions of the Children’s Behavioural Check List (CBCL; (31) ) and the Teacher Report Form 
(TRF; (31) ).The reliability and validity of CBCL and TRF are well established (31,32). Out-
come parameters were the composite scales for internalizing, externalizing and total problems. 
5.3.6 Assessment of potential confounders
Data on pre- and perinatal conditions had been collected during enrolment with the help 
of the Obstetrical Optimality Score (OOS).The OOS describes the obstetrical conditions 
ranging from the parents’ socio-economic status to the infant’s condition immediately after 
birth (33). At the assessment of 18 months, maternal verbal intelligence (IQ) was estimated 
using a very abbreviated version of the Wechsler Adult Intelligence Scale (WAIS III), lim-
ited to the subtest on information and vocabulary (34). At the 9 year follow-up, informa-
tion was collected on parental education and profession, the child’s medical history, family 
composition and nutritional habits.
5.3.7 Statistical analysis 
The cognitive parameters were normally distributed, but none of the other variables were 
normally distributed. The NOS was normalized by  transformation to the fifth power. 
To evaluate the differences in fatty acid composition of the umbilical vein and artery be-
tween children with complex MND and those with a better neurological condition (normal 
or simple MND) and between those with or without dysfunction in a specific neurological 
domain, univariate and multivariate logistic regression analyses were performed. The rela-
tions between prenatal fatty acids and NOS and the relations between prenatal fatty acids 
and cognitive tests were analyzed by use of Spearman correlations and linear regression 
analyses. For the univariate analysis of relationships between neonatal fatty acid status and 
the behavioural data Spearman’s rho was applied. For the multivariate analyses the behav-
ioural data were dichotomized into normal versus borderline range according to Dutch 
norms (31), and analyzed by means of logistic regression analyses. An important potential 
mediator taken into account in the multivariate statistics was postnatal nutritional group 
(LCPUFA supplemented formula, control formula or breastfeeding). In addition, we con-
sidered the following variables as potential confounders: maternal estimated verbal IQ, sex, 
maternal level of education (low versus medium/high), smoking during pregnancy (yes or 
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no), pre-pregnancy maternal body mass index (BMI) and obstetric optimality score (OOS). 
In line with other developmental studies, smoking was dichotomized into no/minimal 
smoking defined as <5 cigarettes per day and evident smoking defined as ≥ 5 cigarettes per 
day (35). Specific attention was paid to the presence of sex – fatty acid status and smoking 
during pregnancy – fatty acid status interactions (see (16)), if an interaction with sex is 
found the data will be presented for each of the sexes separately. All variables were entered 
into the models. A p-value of 0.05 or less was considered as statistically significant. Statisti-
cal analyses were performed using SPSS 15.0 for Windows (SPSS, INC, Chicago IL).
5.4 Results 
Two hundred and thirty five of  the 290 children who were assessed at  18 months and 
of whom data on neonatal fatty acid status were available agreed to participate in the as-
sessment at 9 years (74.1% of the original study group consisting of 317 children, Figure 1). 
Obstetrical data of the study groups and sociodemographic characteristics of the parents 
are described in Table 1. In general, neonatal fatty acid status, obstetrical and social char-
acteristics of the children who were and who were not assessed at 9 years were comparable. 
Yet, children who received LCPUFA supplemented formula were less likely to participate 
in the 9-year-follow-up than the children who received other postnatal nutrition (p < 0.01) 
and maternal verbal IQ of children that participated at 9 yr was significantly higher than 
those that did not participate (p = 0.025). Also, children who did not take part in the follow-
up at 9 year showed lower scores on mental and psychomotor indices of the Bayley Scales 
of  Infant Development than those who did participate (mental index: p = 0.004, median 
difference 3.5 points; psychomotor index: p = 0.005, median difference 3 points). None 
of the neurological, intelligence or behavioural outcomes at 9 years were affected by the site 
of investigation (in the hospital or at home), or by duration of exclusive breastfeeding. No 
interactions between smoking during pregnancy and fatty acid status were found (data not 
shown). Statistical description of the variables can be found in Table 2.
5.4.1 DHA and AA
Univariate analysis demonstrated that DHA in  both the umbilical vein and artery were 
significantly lower in the group of children with complex MND than in the groups of neu-
rologically normal children and children with simple MND (vein p = 0.007, OR: 0.413; 
artery p = 0.044, OR:0.591 Figure 2). Both relations remained statistically significant af-
ter correction for confounders; however, the association between complex MND and ve-
nous DHA was restricted to the boys (Table 3). Two specific neurological domains showed 
an association with neonatal fatty acid status. The children – both boys and girls – with 
dysfunctional posture and muscle tone regulation and the children with dyskinesia had 
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a lower concentration of DHA in the umbilical vein than the children without these specific 
dysfunctions (posture and tone p = 0.023, OR = 0.55; dyskinesia p = 0.017, OR = 0.20). The 
relations remained statistically significant after correction for confounders (Table 3). The 
association between neonatal DHA status and neurological condition was also reflected 
in  the NOS. Multivariate analysis confirmed the association between venous DHA and 
NOS (Table 3). Please note that the NOS used in Table 3 has the transformed scale. An 
effect size of 0.16, as is reported in Table 3, can therefore be interpreted on the original 
scale as follows: a NOS value of 57 transforms to (57/50)5 = 1.9254. Increasing this by 0.16 
gives 2.0854. Transforming this back to the original scale results in 50 x 2.08540.2 = 58.0. 
This means that a change of 1 point in venous DHA is associated with a change of 1 point 
on the original NOS scale. The association was similar for boys and girls. Neonatal DHA 
status was not associated with cognitive and behavioural outcome. Neonatal AA was not 
associated with neurological condition, cognitive and behavioural outcome Interestingly, 
postnatal nutritional group did not play a significant role in any of the observed associa-
tions between neonatal LCPUFA status and neurodevelopmental outcome at nine. 
Table 1. Obstetrical and social characteristics of the infants assessed at 9 years. 
Variable Study group Did not participate 
No. of participants with umbilical cord data assessed 
at 18 months (%)
235 (74.1%) 82 (25.9%)
Nutritional group**
- control formula (CF), n (%)
- LCPUFA supplemented formula (LF), n (%)







Gender, n (%) boys 125 (53.2%) 48 (58.5%)
Birth weight (g), mean (SD) 3547.5 (438.4) 3545.48 (400.3)
Maternal education 
-  high (university education or vocational college), 
n (%) 
-  medium (college graduate or junior vocational 
college), n (%)







Presence of maternal smoking >5cig/day during 
pregnancy, n (%) 
38 (16.2%) 11 (13.4%)
Maternal BMI before pregnancy >18.8 & <24.2, n (%) 128 (54.5%) 43 (52.4%)
Maternal VIQ*, mean (SD) 116.8 (14.9) 112.0 (16.4)
OOS, median (range) 59 (21) 59 (22)
* significant difference p = 0.025
** significant difference p < 0.01 
OOS = Obstetrical Optimality Score
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Table 2. Description of variables used in the statistical analyses.
Independent variables:
DHA vein, median (25th , 75th percentile) 4.24 (3.78 , 4.77)
DHA artery, median (25th , 75th percentile) 4.42 (3.99 , 5.05)
AA vein, median (25th , 75th percentile) 16.53 (15.63 , 17.27)
AA artery, median (25th , 75th percentile) 12.76 (11.69 , 13.97)
TFA vein, median (25th , 75th percentile) 0.703 (0.57 , 0.80)
TFA artery, median (25th , 75th percentile) 0.67 (0.57 , 0.78)
Dependent variables:
MND, % normal, % simple MND, % complex MND 49.4 , 37.9 , 12.8
NOS, median (25th , 75th percentile) 57 (55 , 59)
FIQ, mean (SD) 101.25 (12.75)
Attention and Executive Functions, mean (SD) 10.26 (2.50)
Memory and Learning, mean (SD) 8.82 (2.24)
Language Ability, mean (SD) 9.86 (2.22)
Selective Attention, mean (SD) 7.53 (2.68)
Sustained Attention, mean (SD) 7.91 (2.95)
Attentional Contol/Switching Attention, mean (SD) 8.41 (2.32)
Verbal Memory, mean (SD) 8.33 (3.10)
CBCL Internalizing problems, median (25th , 75th percentile) 52 (46 , 59)
CBCL Externalizing problems, median (25th , 75th percentile) 51 (41 , 57)
CBCL Total problems, median (25th , 75th percentile) 51 (45 , 58)
TRF Internalizing problems, median (25th , 75th percentile) 52 (45.5 , 55)
TRF Externalizing problems, median (25th , 75th percentile) 51 (43 , 57)
TRF Total problems, median (25th , 75th percentile) 50.5 (47 , 55)
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Table 3. Results of  logistic regression analysis of  the contribution of DHA to the complex form 
of Minor neurological Dysfunction (MND), domain of dysfunctional Posture and Tone and do-
main of Dyskinesia and of the linear regression analyses of the contribution of DHA to the Neuro-
logical Optimality Score (NOS).
Contributing 
factors:
Complex MND Dyskinesia Posture and Tone NOS
OR (95%CI) OR (95%CI) OR (95%CI) Effect (95%CI)
Venous DHA 
in total group .119 (.021 , .675)* .425 (.223 , .811)** .16 (.055, .264)**
Venous DHA 
within boys .220 (.079 , .614)**
Venous DHA 
within girls .536 (.176 , -1.63) 
Arterial DHA 
in total group .392 (.206 , .745)** .344 (.118 , 1.006) .596 (.353 , 1.007) 0.109 (.010 , .208)*
The data were adjusted for the following confounders: postnatal nutritional group, gender, OOS, maternal 
verbal IQ, maternal education, maternal smoking during pregnancy, maternal BMI before pregnancy
* significant difference p < 0.05
** significant difference p < 0.01
5.4.2 Trans fatty acids
Neonatal trans fatty acid status was not associated with clinical neurological classification 
or specific neurological domains of dysfunctions. However, venous and arterial trans fatty 
acid status was positively associated with selective attention. Multivariate analyses con-
firmed these associations (Table 4). Trans fatty acid status was not associated with other 
cognitive functions, including other types of attention, and with behaviour at 9 years. 
Table 4. Results of linear regression analyses of the contribution of neonatal venous and arterial 
trans fatty acid status to selective attention. 
Contributing factors Effect (95% CI)
Venous trans fatty acids 2.18 (.601 , 3.755)**
Arterial trans fatty acids 2.71 (1.24 , 4.19)**
The data were adjusted for the following confounders: postnatal nutritional group, gender, OOS, maternal 
verbal IQ, maternal education, maternal smoking during pregnancy, maternal BMI before pregnancy. 
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Figure 2. Neonatal arterial and venous DHA in the whole group (upper panels) and neonatal 
venous DHA separately for boys and girls. The horizontal lines represent median values, the 
boxes the interquartile ranges and the vertical lines the range of values except outliers which 
are depicted by small dots. 
* denotes statistically significant difference; differences between the neurologically normal and 
simple MND vs complex MND: whole group venous DHA p = 0.007, whole group arterial DHA 
p = 0.024, restricted to boys venous DHA p = 0.010.
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5.5 Discussion
The present study indicated that the previously demonstrated association between prenatal 
DHA and neurological development extends at least till the age of 9 years. Higher levels 
of venous DHA were related to less choreiform dyskinesia, less problems in posture and 
muscle tone regulation, a  more optimal NOS, and less complex MND in  boys. Arterial 
DHA was also associated with less complex MND, but in both sexes, and in a more optimal 
NOS in both sexes. Higher levels of TFA in both umbilical cord vessels were related to bet-
ter selective attention scores.
The positive association between DHA and neurological development in the pres-
ent report is in agreement with literature (8,9) and is in line with previous results from our 
study (7). The association suggests that presence of higher neonatal levels of DHA protects 
against clinically relevant complex MND. Detailed analysis revealed that in particular the 
neurological domains choreiform dyskinesia and posture and muscle tone were associated 
with neonatal DHA status. These domains are mediated predominantly by subcortical cir-
cuits in which the striatum plays a major role. Interestingly, animal research demonstrated 
that these circuits accrue the largest amounts of DHA during early development (36).
The protective effect of DHA on the development of minor neurological dysfunc-
tion showed a minor sex effect: a higher venous DHA status was related to less complex 
MND in  boys but not in  girls. Sex differences in  neurological development have been 
reported before (18,37). The current difference may be attributed to the well-known in-
creased vulnerability of boys for neurodevelopmental disorders and MND (37). 
Interestingly, neonatal DHA status was not related to intelligence or any other 
measure of cognition. Intelligence is attributed especially to activity in frontoparietal net-
works (38), parts of the cortex which accrue relatively little DHA during early development 
(36). In line with literature, no associations between umbilical AA levels and development 
at school age are found. This suggests a temporary effect of prenatal AA only.
TFA have been associated consistently with less optimal health in the adult popu-
lation (39). In infants and children, higher TFA levels have been related to reduced birth 
weight and reduced child growth (14,40). As mentioned in the introduction, limited studies 
have been performed relating TFA to neurological development, yet they point to a nega-
tive relation with neurological development. In the present study a minor positive associa-
tion has been found with selective attention. We are unable to offer a biologically plausible 
explanation for this association and suggest this to be a chance finding.
The present study demonstrated an association between neonatal LCPUFA status 
and neurological development at 9, while taking into account postnatal LCPUFA supple-
mentation as a  possible mediator. As the postnatal LCPUFA supplementation did not 
contribute significantly to neurological outcome (17) this implies that especially prena-
tal LCPUFA status affects neurological development. Prenatal LCPUFA status depends on 
maternal LCPUFA consumption during pregnancy and maternal pre-pregnancy LCPUFA 
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status (41). The lack of evidence for a consistent beneficial effect of LCPUFA supplementa-
tion during pregnancy on neurological development(1) suggests that maybe the woman’s 
pre-pregnancy LCPUFA status matters more for the development of her child’s brain than 
LCPUFA consumption during pregnancy. Another intriguing observation is that we did 
not find an interaction between smoking during pregnancy and neonatal fatty acid status. 
This contrasts with the previously reported interaction between smoking during pregnancy 
and postnatal LCUPFA supplementation on cognitive development: children prenatally ex-
posed to LCPUFA supplementation benefited in some cognitive domains from postnatal 
LCPUFA supplementation, whereas children not exposed to maternal smoking did not 
(16). It is conceivable that the direct competing effect of prenatal smoking abolishes the 
potentially additional positive effect of LCPUFA on neurodevelopment. 
The present study is a secondary analysis of data from a randomized controlled trial 
on formula supplementation. This may be considered a limitation as the supplementation 
could have acted as a mediator. Yet, the multivariate analyses showed that postnatal nu-
tritional group did not affect neurodevelopmental outcome. A secondary limitation is the 
sample size, this may be considered too small to draw strong conclusions. A more serious 
limitation of the present study is the attrition of 25.9%. However, a certain amount of at-
trition is considered inevitable in longitudinal studies (42) and attrition of less than 30% 
over a time period of 9 years may be considered acceptable. Unfortunately, attrition was 
selective, as children taking part in the present follow-up had higher scores on the devel-
opmental tests at 18 months.
The strengths of the study are the long term follow-up period, the detailed prenatal 
and perinatal documentation, the elaborate neurological, cognitive and behavioural test 
battery and the multivariate analyses with a  large set of possible confounders, including 
smoking during pregnancy and estimated maternal verbal IQ. 
In conclusion, the present study showed that higher neonatal DHA levels are asso-
ciated with a more optimal neurological development at 9 years of age. Neonatal DHA was 
not associated with cognition or behaviour at 9 and neonatal AA was not associated with 
any neurodevelopmental parameter at 9. The study suggests that prenatal DHA levels have 
a larger impact on neurological development than postnatal DHA levels.
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It is clear that LCPUFA are important elements of the human nervous system. However 
their exact role in human development, and more specifically the effect of early postnatal 
AA and DHA supplementation on the development of the nervous system at age 9 as well 
as the relation between neonatal DHA, AA and trans fatty acid concentrations and develop-
ment of the nervous system at age 9 had not been assessed. 
In the current follow-up no consistent effects of postnatal AA and DHA supple-
mentation on neuro-motor, cognitive, behavioural, anthropometric and cardiovascular 
development were found. Looking at the separate indices, we found that none of the neuro-
motor indices was related to AA and DHA supplementation. The effects on cognitive tests 
were complex due to an interaction with maternal smoking during pregnancy. In children 
exposed to smoking during pregnancy LF was associated with higher scores on verbal IQ 
and learning and memory, in children not exposed to smoking during pregnancy LF was 
associated with lower scores on verbal memory. The whole LF group scored worse than the 
CF group on executive function. With respect to the cardiovascular and anthropometric 
indices, no relations with postnatal LCPUFA supplementation were found.
Breastfeeding was related to better fine manipulative abilities. It was also to some 
extent associated with a higher IQ, breastfed children demonstrated a higher IQ than chil-
dren who had received control formula and had been exposed prenatally to smoking. In ad-
dition, breastfed children showed a marginally lower heart rate than formula fed children.
Neonatal DHA levels were associated with neuro-motor development: children 
with complex minor neurological dysfunction showed lower mean DHA values than chil-
dren with better neurological condition, for the venous DHA levels this effect was restricted 
to the boys. The neurological domains which were associated in particular with lower ve-
nous mean DHA values were dysfunctional posture and tone regulation and dyskinesia. 
Neonatal AA values were not associated with neurological outcome. Neither neonatal DHA 
nor AA values were associated with cognition and behavior at age 9. Trans fatty acid levels 
were positively associated with selective attention, both in the vein and in the artery. 
6.1 Effects of postnatal LCPUFA supplementation
The relation between neurological structure development and function is far from clear 
cut. This means that it is quite difficult to relate the effects of LCPUFA supplementation 
on a neuronal level to enhanced or possibly diminished test results in children. The ba-
boon study by  Diau (1) demonstrated that LCPUFA accumulate mainly in  the cortical 
grey matter, predominantly in the synaptic membranes, and to a lesser extent in the white 
matter. The study by Diau also demonstrated that the highest concentrations of LCPUFA 
were found in the basal ganglia, precentral, postcentral, prefrontal and occipital cortices, 
hippocampus, thalamus and cerebellum. This indicates that LCPUFA intake might affect 
in particular circuitries involved in sensorimotor integration, motor learning, intelligence, 
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executive functions, attention, and memory (2). Other animal studies indicated that LCP-
UFA status in early life may affect dopaminergic and serotonergic circuitries. Functions 
subserved by these systems are for instance attention regulation, aggression and mood (3).
In the current study effects of postnatal LPUFA supplementation were found on 
verbal IQ, learning and memory, verbal memory and executive function (although the lat-
ter was a negative effect). No associations have been found with neuro-motor development, 
language function, full IQ, performance IQ, selective attention, sustained attention, switch 
attention, cardiovascular and anthropometric indices.
The cognitive functions that were associated with LCPUFA supplementation are 
in line with the work of Diau. However, based on that work more functions could have been 
expected to be associated with the LCPUFA association. Also, not all findings are in the ex-
pected direction. The cognitive and neuro-motor functions tested in the current study are 
complex tasks. Complex tasks are the result of the performance of networks of brain regions 
that integrate vast amounts of information. The developmental process of such networks 
requires the coordination and integration of a multitude of factors, among which genetic 
programs, environmental exposures and personal experiences. Nutrition is an important 
factor, however it is but one of the many factors that influence neuronal development. This 
could imply that the influence of nutrition may be diluted. Also, the study by Diau dem-
onstrated that not all regions are equally influenced by LCPUFA supplementation (1). This 
suggests that even though important parts of a network may profit from higher LCPUFA 
levels, the entire network may not show a related improved functioning due to limitations 
in other parts of this network that have not profited from this advantage. Last but not least 
the developing baboon brain is not identical to the developing human brain.
The effects of  LCPUFA supplementation depended for a  large part on maternal 
smoking. Children having been exposed to maternal smoking during pregnancy (mean-
ing more than 5 cigarettes per day) showed a positive effect of LCPUFA supplementation 
on VIQ and learning and memory. Children that were not exposed to maternal smoking 
during pregnancy showed negative effects of LCPUFA supplementation on verbal memory. 
According to work by Agostoni (4) maternal smoking during pregnancy causes diminished 
LCPUFA levels in infants, both omega 6 and omega 3, as was measured shortly after birth. 
This may be related to the IQ drop of 8 points that was found as a result of smoking during 
pregnancy in the current study (see Table 2 chapter 3). Supplementing LCPUFA via for-
mula may partly compensate for this detrimental effect, something that has been suggested 
in literature (5). 
No associations were found between LCPUFA supplementation and blood pres-
sure, heart rate, weight, height, BMI or head circumference. This confirms to part of the 
literature (6,7). Next to studies where no associations between LCPUFA supplementation 
and cardiovascular and anthropometric were found, some studies did report associations, 
both positive and negative (8-11). This inconsistency is most likely due to the large hetero-
geneity in study methods (see Table 1 chapter 4).
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Important in interpreting the results of the current study is the selective attrition 
of LF children with a lower cognitive performance on the age of 18 months. This indicates 
that the results of the LF group could in reality be more negative. Another important fac-
tor to take into account is the relatively short supplementation period of 2 months. The 
Groningen LCPUFA study was part of a set of three supplementation studies. Each study 
featured a different supplementation period, either 2, 4 or 6 months. One may argue that 
a 2 month period is too short, taking into consideration that the infant in this period is to 
be exclusively formula fed and has a continued need of DHA and AA until at least the age 
of 16 weeks. At that point the ability of the infant to synthesize its own DHA covers about 
its own need (12). Taking this short period into consideration it is important to realize that 
the results coming from this study may present an underestimation of the supplementation 
effect, if supplied during the entire period until weaning. In this respect the review of Sim-
mer (13) is important. The review assessed a large set of studies that evaluated the effect 
of  LCPUFA supplementation. In this large set the supplementation period ranged from 
2 months (the current study) until over 1 year. The results from the studies that supple-
mented for a short period did not differ from those supplementing a longer period. Simmer 
concluded that no beneficial effects of LCUPFA supplementation were found (13). How-
ever, looking carefully and taking into account age at outcome, a slightly different picture 
arises. Studies evaluating the effect of supplementation before the age of 4 months did find 
an advantage for DHA supplementation, studies evaluating this effect after the age of  4 
months did not (14). 
6.2 Effects of breastfeeding
In literature, general positive effects of breastfeeding on neuro-motor development (15) 
and cognitive development (16-19) have been reported. An important role in this advan-
tage of breastfeeding over formula feeding is played by social economical factors such as 
maternal IQ and social economic status, the advantages of breastfeeding become attenu-
ated when adjusted for these variables (20-22). Which is the reason that in the current the-
sis all findings were adjusted for a series of factors among which a proxy of maternal verbal 
IQ and ses. A second possible explanation for the advantage of breastfeeding over formula 
feeding is the nutritional difference. One of these differences is the presence of LCPUFA. 
This is present in human milk and until recently not in formula (23).  
Building on the above mentioned assumption that the presence of LCPUFA plays 
a role in the advantage of breastfeeding over formula feeding, it is expected that regions 
benefitting from LCPUFA supplementation (1) would be the ones demonstrating a breast-
feeding advantage. These are in  particular circuitries involved in  sensorimotor integra-
tion, motor learning, intelligence, executive functions, attention, and memory. Breastfed 
children were found to demonstrate a slightly better development than formula fed chil-
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dren, they demonstrated less fine manipulative dysfunction when compared to both for-
mula groups and also improved IQ was found in those children that had been exposed to 
smoking during pregnancy when compared to the un-supplemented formula group. These 
differences point towards the circuitries mentioned above, however one could have ex-
pected more differences. This dissociation between our findings and our expectations may 
be explained by  the same factors that have discussed before: nutrition is but one of  the 
many factors influencing neuronal development, not all regions in the neuronal network 
profit equally from the higher LCPUFA levels and there is fundamental difference between 
the developing baboon brain (on which a large part of our expectations are based) and the 
developing human brain.
Smoking during pregnancy is found to be an interacting factor, similar to the sup-
plementation effect reported in an earlier section. The IQ of children exposed to smoking 
during pregnancy was higher when breastfed in comparison to children fed control formu-
la. This suggests that breastfeeding, containing LCPUFA, compensates for the diminished 
LCPUFA levels of children that is a result of maternal smoking during pregnancy (4). This 
corresponds to the work of Batstra (5), who showed that the negative effects of maternal 
smoking during pregnancy on cognitive development at age 9 were countered by breast-
feeding. 
Generally speaking, in the current thesis a less than expected number of neuro-mo-
tor and cognitive abilities were found to differ between breastfed and formula fed children. 
Based on the literature differences were expected in the field of general neurological devel-
opment (15) and general cognitive development (16,19), in the latter case most notably IQ 
(17,18). An important role in this respect may be played by the adjustment in all analyses 
for a series of factors among which a proxy of maternal verbal IQ and social economical 
status, as mentioned earlier this is known to attenuate differences between formula fed and 
breastfed infant development.
In addition to neuro-motor and cognitive development, attention was also paid to 
cardiovascular and anthropometric development. No associations were found with blood 
pressure. In an important review, presenting the blood pressure differences between groups 
of breastfed versus formula fed infants, Martin (24) concluded that these groups indeed 
seemed to differ. A pooled difference between breastfed and formula fed infants of 1.4 mm 
Hg systolic blood pressure and 0.4 mm Hg diastolic blood pressure was found after the age 
of 12 months. A difference of this magnitude could also be expected in the current study. 
Unfortunately our study was underpowered to detect such a  subtle difference. Post-hoc 
power analyses using a α = 0.05 and a power of 0.8 indicated that the study was capable 
of detecting a difference of minimally 1.5 mm Hg. This means that with regard to blood 
pressure we can only conclude that there is no difference between the groups of more than 
1.5  mm Hg. As a  second cardiovascular parameter we measured heart rate. A  lowering 
of 2 beats per minute was found in  the breastfed group. Resting heart rate may be con-
sidered to be a simple measure of vagal function (25). A minor decrease in heart rate may 
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therefore indicate a shift in autonomic control in which there is a minor increase in vagal 
dominance. The latter is known to be associated with decreased risk of diabetes, hyperten-
sion and mortality in later life (25).
The anthropometric development of  the children was measured in  body length, 
weight (resulting also in BMI) and head circumference. No differences between breastfed 
and formula fed children were found. Based on the literature a small reduction of obesity 
in later childhood could be expected (26,27). Also with respect to the anthropometric pa-
rameters our study was slightly underpowered; using α = 0.05 with a power of 0.8 the study 
was capable of detecting a difference in weight of 1.5 kg and a difference in height of 1 cm. 
This means that subtle differences could not be detected. Obesity development is known to 
be related to length of breastfeeding. In the current study 53% of mothers gave maximally 
8 weeks full breastfeeding. This is a relatively short period, in that it is much shorter than 
the length of 6 months exclusive breastfeeding as advised by the WHO (28), however it is 
representative for the Dutch feeding practices (29). 
6.3 Effects of neonatal LCPUFA status 
The neonatal evaluation in the current study evaluated DHA, AA and transfatty acid levels 
in the umbilical cord and its associations with development at age 9.
Fatty acid levels in the vessel walls of  the umbilical vein and artery reflect nutri-
tional supply and use during pregnancy. The umbilical vein transports the blood from the 
mother to the foetus and the umbilical artery transports the blood from the foetus back to 
the mother. Therefore fatty acid content of the vein can be seen as a reflection of nutritional 
supply and the fatty acid content of the artery as a reflection of foetal use. Higher DHA 
levels at birth were found to be related with a better neuro-motor condition, this confirms 
to literature (30,31) and is in line with our previous results at the age of 18 months (32). 
Looking more specifically to the separate neuro-motor domains we found that 
in particular the domains choreiform dyskinesia and posture and muscle tone were found 
to be related to DHA levels. These domains are mediated predominantly by the subcorti-
cal circuits in which the striatum plays a central role. These subcortical circuits have been 
shown to benefit from DHA supplementation (1). 
Detailed analyses revealed that the association between venous DHA and general 
neuro-motor development was restricted to boys and that for arterial DHA no sex differ-
ence was present. Sex differences in neurological development have been reported before. 
A robust finding is a 10% overall larger brain size and cerebellum size (corrected for total 
brain size difference) for boys (33-38). Also, the developmental trajectories of gray mat-
ter volume and cerebellar volume differ between the sexes (gray matter volume peak size 
in boys at 14.5 years, in girls at 10.5 years; cerebellar volume peak size in boys at 15.5 years, 
in girls at 12 years (39,40). Relevant subcortical structures that show gender related differ-
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ences are the caudate (generally found to be larger in girls (38,41-43)), the amygdala (gen-
erally found to be larger in males (44-46)) and the hippocampus (found to be larger in fe-
males (47)). Both the amygdala and the hippocampus differ in sex steroid receptors, the 
amygdala features higher androgen receptor levels and the hippocampus features higher 
estrogen receptors (48,49), indicating a possible hormonal role in neuronal gender differ-
ences. The size of the basal ganglia, including the caudate, and the gradual decrease of this 
structure has been related to neurodevelopmental disorders such as ADHD (50) and ob-
sessive-compulsive disorder (51) for which boys are known to be more sensitive than girls.
In the present study we found a gender difference, the relationship between venous 
DHA and neuro-motor development was restricted to boys. This may be related to the 
above mentioned sex difference in brain development as the basal ganglia are also known 
to benefit from higher DHA levels (1). Not only was there a sex difference with respect to 
neuro-motor development, there was also a difference in relation between vein and artery. 
The relationship between DHA and neuro-motor development was present in boys only 
in the vein and not in the artery. This may indicate that boys are more dependent than girls 
on supply of DHA for their neuro-motor development, suggesting that DHA-supply may 
be a bottle neck in their development. 
No associations were found between AA levels and any of the outcome measures 
at age 9. This corresponds to literature were only a relation between prenatal AA levels and 
development is found at a very young age (52-54). 
An unexpected finding was the positive association between trans fatty acid levels, 
both in vein and artery, and selective attention. There has been little research on the effects 
of trans fatty acids. The studies that have been done reveal negative associations between 
trans fatty acids and growth in infants and children (55-59) and negative associations be-
tween trans fatty acids and general neurological development at young age (32,52). Little is 
known about the neuronal circuits supporting specifically selective attention (2). However 
as part of more complex processes, such as cognitive control, areas such as the supplemen-
tary motor area, the frontal eye fields, anterior cingulate cortex, dorsolateral prefrontal cor-
tex, ventrolateral prefrontal cortex, lateral orbitofrontal cortex, and the temporal and pari-
etal regions, have been mentioned (60-62). The association between selective attention and 
transfatty acids suggest that transfatty acids may specifically affect these regions. However, 
the process of cognitive control, and its underlying neuronal circuits, are closely related to 
executive functioning, an outcome not affected by transfatty acids in the current study. The 
authors know of no biologically plausible explanation for this contradictory finding. No 
relations were found between trans fatty acids and any of the other indices. 
No associations were found between prenatal DHA and cognitive or behavioral 
outcomes. This confirms to literature, studies reported no associations between prenatal 
DHA and general cognitive development at 18 months (32,63), at 2.5 years (64) , at 4 years 
(65) and at 7 years (66,67). There is one exception, a study by Boucher et al. who reported 
a positive association between neonatal DHA and memory at a mean of 11 years (68). The 
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discrepancy between the findings of Boucher et al. and the rest of the literature may be ex-
plained by differences in the characteristics of the studied groups. In the studies reporting 
no associations all children were from western low fish consuming communities having 
received DHA supplementation. The study by Boucher et al. was performed in an Inuit 
population, which is known for its generally high fish and therefore DHA consumption.
6.4 Attrition
The follow-up at 9 years was completed in 72% of the original population. Long term fol-
low-ups inevitably suffer from attrition. Loss to follow-up depends on length of  follow-
up, age of  the subject, nature and perceived benefit of  the test, degree of  inconvenience 
involved and the ability to trace and contact subjects (69). Based on the above mentioned 
criteria the current study could be expected to suffer from high attrition: the follow-up 
period is long, a high percentage of children had moved from their original address, the 
perceived benefit of the tests are low (the population being healthy) and the session was 
a  lengthy 3 hours. Taking these unfavorable factors into account a much larger attrition 
might have been expected. 
Next to a general attrition, the study also suffered from selective attrition. There was 
a general loss of children having shown significantly more often normal-optimal general 
movements at 3 months. Meaning we have a neurologically less optimal group of children 
remaining in the study. Additionally, restricted to the LF group a larger percentage of boys 
than girls was lost and also children with a worse cognitive development as measured at 18 
months. Taking all factors into account we consider an attrition of 28% favorable, however 
due to the selective nature of this attrition it is important in the interpretation of the results 
to be aware of the LCPUFA group being a more positive selection of children than the other 
two groups. Important in this respect is the comparison of this study to other studies in the 
field. Interestingly, in the Cochrane review of Simmer et al. the level of attrition of the cur-
rent study was considered as favorable, allowing for a classification as ‘moderate to low risk 
of bias’ (13). 
6.5 Conclusions
This thesis shows that LCPUFA supplementation of formula during the first two postnatal 
months in healthy term infants does not promote neuro-motor condition at school age. 
Neither seemed LCPUFA supplementation to be associated with a  beneficial effect on 
cardiovascular and anthropometric development. However, indications were found that 
LCPUFA supplementation affected cognitive development. The effect was dependent on 
maternal smoking status during pregnancy. LCPUFA supplementation of infants prenatally 
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exposed to smoking was associated with a beneficial effect on cognition at 9 years, whereas 
LCPUFA supplementation of infants who had not been exposed to maternal smoking dur-
ing pregnancy was associated with a minor but statistically significant negative effect on 
cognition at 9.
Breastfeeding – in comparison to formula feeding – was associated with a slightly 
better neuro-motor outcome, marginally better cardiovascular outcome and improved 
cognitive abilities. 
Finally the studies included in the present thesis indicate that neonatal fatty acid 
status had an effect on developmental outcome. Higher DHA levels at birth were associated 
with a more optimal neuro-motor development at school age and higher trans fatty acid 
levels were associated with improved selective attention. DHA and AA were not associated 
with cognition and behavior at 9.
6.6 Future research
The current study is the first to evaluate broadly neurological development at school age af-
ter early postnatal LCPUFA supplementation. The supplementation period of two months 
was relatively short. It would be interesting to investigate whether a longer supplementation 
period, e.g. 6 months, akin to the advised period in which the infant is exclusively depen-
dent on breastfeeding or formula feeding, would yield different results.
The next step for the current study might be evaluation at puberty. A period of great 
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This thesis covers two main subjects. Firstly, it investigates the effects of  supplementa-
tion of infant formula with two Long-Chain Poly Unsaturated Fatty Acids (LCPUFA): the 
omega-3 fatty acid docosahexaenoic acid (DHA) and the omega-6 fatty acid arachidonic 
acid (AA) during the first 2 months after birth on developmental outcome at school age. 
Secondly, the thesis evaluates relationships between fatty acids as measured in the umbilical 
cord vessel walls and child development at school age.
Women were recruited while pregnant. If a healthy at term infant was born, the in-
fant was enrolled in the study. The majority of participating families donated umbilical cord 
tissue. The infants who were formula fed were randomly assigned to either of two groups. 
One group received standard formula (control group) the other group received LCPUFA 
supplemented formula (LCPUFA group). The study was performed in a double blind fash-
ion, meaning that neither parents nor researchers were informed on group allocation. In 
addition a group of infants whose parents chose to breast feed, were included in the study 
as a reference group. 
The literature indicates that DHA and AA supplementation of formula in healthy 
term infants is related to better development during the first 3 or 4 months after birth, but 
that this effect has disappeared at the age of 1.5–2 years. This does not necessarily imply 
that the effect has disappeared permanently; it is also possible that with increasing age the 
effect will be re-expressed. Such an effect is known of breast feeding: absent at 1.5–2 years 
and present at school age and in adulthood. 
No other studies to date have reported on the long-term effects of LCPUFA sup-
plementation of  formula on development at 9 years. In the current study, the effects on 
neuro-motor development, cognitive development, behaviour, body length, weight, head 
circumference, blood pressure and heart rate have been evaluated.
No differences were found in  neuro-motor development between the two for-
mula groups. Effects on cognitive development were found to be dependent on maternal 
smoking during pregnancy. In the group of  children who were born to smoking mothers 
LCPUFA supplementation was associated with higher scores on verbal IQ and learning 
and memory. In the group of children of non-smoking mothers LCPUFA supplementa-
tion was associated with a lower score on verbal memory. In addition, children who had 
received LCPUFA supplementation had slightly lower scores on executive functions than 
the children who had received control formula. The latter effect was not dependent on 
maternal smoking status during pregnancy. No differences were found between the two 
formula groups with regards to behaviour, weight, body length, head circumference, blood 
pressure and heart rate.
Being breastfed was associated with a minor advantage in neuro-motor develop-
ment and cognitive development. Breast fed children demonstrated slightly better fine 
manipulative skills than formula fed children. The effect on cognitive development was 
mediated by maternal smoking during pregnancy. In the children who were exposed to 
maternal smoking during pregnancy a higher IQ was found in breastfed children compari-
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son to formula fed children. The children who had not been exposed to maternal smoking 
during pregnancy did not demonstrate breastfeeding related cognitive advantages. Also, no 
differences were found between breast and formula feeding for any of the other cognitive 
functions, nor for behaviour, weight, body length, head circumference and blood pressure. 
For heart rate a small advantage was found for breastfed children, their heart rate was lower 
than that of formula fed children.
The second part of the study addressed relationships between fatty acids in the um-
bilical vessel walls and development at age 9. The fatty acid profile of the umbilical vessel 
walls may be regarded as a proxy of prenatal fatty acid status. In the analyses a potentially 
confounding effect of postnatal group allocation was taken into account. The analyses re-
vealed that higher DHA levels in the umbilical vein were related to less choreiform move-
ments, less posture and muscle tone problems and a lower prevalence of the clinically rel-
evant form of minor neurological dysfunction, i.e. the complex form of minor neurological 
dysfunction. No associations were found between DHA and cognition or behaviour. Also, 
AA did not show any relations with development at age 9.
To summarize, the data of the present study indicate that a higher prenatal DHA 
level is associated with a better neurological outcome at 9 years, without affecting cognition 
and behaviour. Prenatal AA was not associated with developmental outcome at 9. The study 
was unable to demonstrate a consistent beneficial effect of postnatal supplementation with 
DHA and AA on outcome at 9 years. The effect of postnatal DHA and AA largely depended 
on maternal smoking status during pregnancy. With respect to breastfeeding: our study 







Dit proefschrift heeft twee hoofdonderwerpen. Als eerste behandelt het het effect van toe-
voegen van het omega-3 vetzuur docosahexaeenzuur (DHA) en het omega-6 vetzuur, ara-
chidonzuur (AA) via de flesvoeding gedurende de eerste 2 maanden van het leven op de 
ontwikkeling van het kind op 9 jaar. Het tweede hoofdonderwerp is de relatie van verschil-
lende vetzuren zoals gemeten in de navelstreng met de ontwikkeling van kinderen op 9 jaar. 
Zwangere vrouwen werden gevraagd mee te doen aan het onderzoek. Als de vrou-
wen, bevielen van een gezond op tijd geboren kind mochten de moeder-kind paren mee-
doen aan het onderzoek. Een aanzienlijk deel van de moeders doneerde na de geboorte 
navelstreng weefsel. De kinderen waarvan de ouders kozen voor het voeden met flesvoe-
ding werden verdeeld in twee groepen. De ene groep kreeg standaard flesvoeding (de con-
trole groep) en de andere helft kreeg flesvoeding met daaraan DHA en AA toegevoegd 
(de LCPUFA groep). De verdeling werd door het lot bepaald – dit wordt een Randomized 
Controlled Trial genoemd. Het onderzoek werd dubbelblind uitgevoerd, dat wil zeggen dat 
zowel ouders als onderzoekers niet wisten welk kind welke voeding kreeg. Ontwikkeling 
werd ook in een derde groep bestudeerd, namelijk van kinderen van wie de ouders kozen 
voor borstvoeding. Deze groep fungeerde als referentiegroep. 
Uit de wetenschappelijke literatuur was bekend dat DHA en AA toevoeging aan 
flesvoeding een positief effect heeft op de ontwikkeling gedurende de eerste 3 à 4 maanden 
na de geboorte, maar dat de effecten op de leeftijd van 1,5 à 2 jaar verdwenen zijn. Dit 
hoeft echter niet te betekenen dat het effect helemaal verdwenen is, het is ook mogelijk 
dat het effect tijdelijk verdwenen is en met de verdere ontwikkeling van de hersenen weer 
te voorschijn komt. Zo is een effect van borstvoeding ook niet aantoonbaar op 1,5-2 jaar, 
maar toonde men wel kleine, positieve effecten op de ontwikkeling op de schoolleeftijd en 
in de volwassenheid. 
Geen onderzoek bestudeerde de effecten van het toevoegen van LCPUFA aan fles-
voeding op de lange termijn ontwikkeling, dat wil zeggen de ontwikkeling op de school-
leeftijd. Het huidige onderzoek bestudeerde de effecten op neuro-motore ontwikkeling, 
cognitieve ontwikkeling, en het gedrag, als ook die op lengte, gewicht, hoofdomtrek, bloed-
druk en hartslag.
Het huidige onderzoek toonde aan dat er geen verschil was in neuro-motore ont-
wikkeling tussen de beide flesgevoede groepen. De effecten op de cognitie bleken samen 
te hangen met het wel of niet roken van de moeder tijdens de zwangerschap. Kinderen van 
rokende moeders hadden een voordeel van de aanwezigheid van LCPUFA in de flesvoe-
ding voor wat betreft hun verbale IQ en hun leren en geheugen. Kinderen van niet rokende 
moeders hadden een klein nadeel van de aanwezigheid van LCPUFA in de flesvoeding voor 
hun verbale geheugen. Verder was de aanwezigheid van LCPUFA bij alle kinderen (of de 
moeder nu al of niet gerookt had tijdens de zwangerschap) geassocieerd met een licht ne-
gatief effect op de planningsfuncties van de kinderen. Er waren geen verschillen aanwezig 
tussen de beide flesgevoede groepen in gedrag, gewicht, lengte en hoofdomtrek en ook niet 
in bloeddruk en hartslag. 
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Borstvoeding hing samen met een klein voordeel in de neuro-motore en de cogni-
tieve ontwikkeling in vergelijking met de flesvoeding. Borstgevoede kinderen hadden iets 
betere fijne manipulatieve vaardigheden en bij de kinderen die een moeder hadden die 
gerookt had tijdens de zwangerschap werd een wat hoger IQ gevonden. Voor de kinderen 
van een moeder die niet rookte tijdens de zwangerschap was er geen verschil tussen de fles-
gevoede en borstgevoede kinderen. Ook waren er geen verschillen tussen borst- en flesvoe-
ding voor de andere cognitieve functies, noch voor gedrag, gewicht, lengte, hoofdomtrek 
en bloeddruk. Voor hartslag was er een klein voordeel voor de borstgevoede kinderen, hun 
hartslag was wat lager. 
Als laatste hebben we gekeken naar de effecten van de vetzuren zoals die gemeten 
zijn in de navelstreng. De vetzuurstatus in de wand van de navelstrengvaten weerspiegelt 
de prenatale vetzuurstatus. Deze geven een beeld van de vetten in de voeding die het kindje 
heeft gehad tijdens de laatste periode van de zwangerschap. De concentratie van verschil-
lende vetzuren werd in verband gebracht met de neuro-motore, cognitieve en gedragstoe-
stand van het kind op 9 jaar. In de analyses hielden we rekening met de postnatale voe-
dingsgroepen. We vonden een verband tussen DHA en neuromotore ontwikkeling: meer 
DHA in de navelstrengader hing samen met minder choreiforme (onwillekeurige) bewe-
gingen, minder problemen in de regulatie van houding en spierspanning en een in zijn 
algemeenheid betere neuromotore conditie.
Samenvattend kunnen we zeggen dat hogere DHA-niveaus voor de geboorte meer 
effect lijkt te hebben op de neuromotore ontwikkeling dan DHA toevoeging aan flesvoe-
ding gedurende 2 maanden na de geboorte. Daarnaast kunnen we zeggen dat DHA en AA 
toevoeging aan de flesvoeding een niet-eenduidig effect lijkt te hebben op de ontwikkeling 
op 9 jaar. De aard van het effect hangt af van het al dan niet gerookt hebben van de moeder 
tijdens de zwangerschap. Ons onderzoek bevestigd andere onderzoeken die aangeven dat 
borstvoeding geassocieerd is met een klein positief effect op de ontwikkeling van hersenen 






Het schrijven van een proefschrift is een proces dat veel tijd en energie kost. In mijn geval 
wat meer tijd dan vooraf gepland. Maar zoals ik vooraf hoopte is het de tijd zeker waard 
geweest. Er zijn veel mensen die in deze periode een grote rol hebben gespeeld en zonder 
wie dit proefschrift er niet was gekomen. 
Als eerste man en kind. Mark jij bent vrij vlot na het beginnen van dit proefschrift in mijn 
leven gekomen en kent mij dus ook alleen maar als iemand die een aanzienlijk deel van 
haar tijd hieraan besteedt. Ik hoop je na de afronding te kunnen laten zien dat ik, ook al 
hoort een bepaalde mate van overwerk bij de wetenschap, een groot deel van mijn tijd 
liever aan andere dingen besteed. Wisse, mijn lieve wandelende dinosaurus encyclopedie. 
Mamma kijkt er naar uit om nog meer van jou te kunnen leren en uren met je te kletsen 
over je Micropachycephalosaurussen en je Liopleurodons.
Lieve familie: Lummie, Lida, Elly, Robert, Esmee, ooms, tante, schoonfamilie. Ook jullie 
hebben een flinke periode mijn verhalen over dit proefschrift moeten aanhoren. Op mo-
menten heel positief maar soms ook aardig wat gemopper. Nu is het klaar en kunnen we 
het over nieuwe dingen hebben!
Prof. Dr. Mijna Hadders-Algra, mijn promotor. Je runt een afdeling op een zeer strakke ma-
nier en hebt de gave om, ondanks het feit dat je zeer veel projecten managet, altijd goed op 
de hoogte te blijven van alle details en daarnaast ook snel stukken door te nemen. Nu ik zelf 
meerdere projecten manage en mensen begeleid zie ik pas hoe ontzettend moeilijk dit is. Ik 
hoop jouw vaardigheid op dit gebied ooit te kunnen benaderen. Bedankt voor al je input.
Beste leden van de leescommissie, Prof. Dr. Verkerke, Prof. Dr. Tucha en Prof. Dr. Hornstra. 
Mijn dank voor het beoordelen van het proefschrift. Een tijdrovende en niet te onderschat-
ten taak.  
Lieve collega’s van de ontwikkelingsneurologie. Victorine, Cornill, Kirsten, Karin, Hylco en 
Saskia, eigenlijk de ‘oude garde’ in mijn herinnering. We hebben roerige tijden meegemaakt 
met ups en downs maar altijd was de onderlinge sfeer goed en de koffiepauze gezellig, mijn 
dank voor jullie input! Hedwig, jij kwam binnen voor een studentenproject maar bleef als 
MDPhD-er. Jij hebt mij ondersteund tijdens een groot deel van het project en mijn taak 
zeker lichter gemaakt. Mijn dank voor je harde werken en daarnaast het luisterende oor en 
de gezelligheid. Jouw promotie zal vlot volgen op de mijne, het is je gegund! Lieke Peters, 
Lieke van Baalen, Marjolein, Tjitske, Elisa en anderen, ook met jullie heb ik vele uurtjes 
doorgebracht en aardig wat koppen koffie gedronken, mijn dank!
Loes, secretaresse van de ON. Je hebt het bijzondere vermogen precies door te hebben wat 
er speelt en weet op bijzonder gevoelige wijze hierin te ondersteunen. Mijn dank hiervoor! 
Dankwoord
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Michiel, de technische man. Wat heb ik je vaak moeten lastigvallen omdat MSword weer 
eens allerlei mysterieuze dingen aan het doen was. Helaas vaak zonder logisch aanwijsbare 
reden maar altijd kwamen we tot een oplossing. Mijn dank.
Leo, we hebben niet zo lang samengewerkt op de ON maar je hebt een blijvende indruk 
achtergelaten. Op mijn nieuwe werkplek hebben we elkaar weer getroffen en werken we 
samen om jouw draagbare EMG apparaat te valideren, tot mijn grote plezier.
Prof. Dr. Vaclav Fidler, statistiek is prachtig, een soort van toverdoos gevuld met de meest 
magische instrumenten waar bij vlagen prachtige en begrijpelijke maar ook bij vlagen vol-
ledig onnavolgbare resultaten uitkomen. U hebt het vermogen deze magische instrumen-
ten om te zetten in logische en begrijpelijke processen en daardoor statistiek tot een bruik-
baar geheel te maken. Mijn dank hiervoor.
Ondanks dat mijn proefschrift aan het einde van mijn contract tijd niet af was, ben ik gaan 
werken als onderzoeker op de huisartsgeneeskunde onder prof dr. T. van der Molen. Beste 
Thys, je nam een risico om een niet gepromoveerde onderzoeker aan te nemen op een 
post-doc plek. Je zult je gedurende de periode dat het duurde voor het af was zeker wel eens 
vertwijfeld achter de oren gekrabd hebben. Maar nu is het eindelijk af. Ik wil je bedanken 
voor het vertrouwen en het overnemen van mijn opleiding als onderzoeker. Je hebt een 
duidelijk andere stijl dan ik gewend was en de overgang is bij vlagen wel eens lastig geweest 
voor me maar ik heb er bijzonder veel van geleerd en ben er een nog betere onderzoeker 
van geworden. Ik hoop nog vele jaren op deze plek te kunnen blijven werken. 
Siebrig, Helma, Bertine, Janwillem, Thecla, Esther, Frederik, Ioanna, Onni, Roland en mijn 
andere collega’s op de huisartsgeneeskunde. Ik heb het geluk dat ik op een afdeling werk 
waar de mensen op zo’n prettige en open manier samenwerken. Ik wil jullie danken voor 
jullie gezelligheid, adviezen en steun!
Mijn paranimfen, mijn broer Robert en vriendin Anneke, wil ik bedanken voor het mij 
bijstaan in een ingewikkelde periode.
Mijn lieve vrienden en vriendinnen! Jacolien en Richard, Ko en Hennie, Jos en Mier, An-
neke en Carol, Jan, Jim en Vic en vele anderen. Mijn dank voor het aanhoren van mijn ver-
halen en het steunen tijdens de lastige momenten. Ik voel me dankzij jullie een rijk mens!
Eigenlijk als allerbelangrijkste wil ik de kinderen en ouders danken die hebben meegedaan 







Corina de Jong werd geboren op 29-06-1980 te Heerenveen. Na enkele verhuizingen ging 
ze op 19 jarige leeftijd in Groningen Psychologie studeren. Groningen zou de rode draad 
in haar carrière blijken. 
Tijdens haar studie lonkte het buitenland en DaimlerChrysler lonkte terug met een 
afstudeerstage. Stuttgart werd haar nieuwe haven en onderzoek naar de menselijke factor 
in  de auto bracht haar een eerste leuke en interessante stap op de arbeidsmarkt. Daim-
lerChrysler USA was de volgende. In 2005, na het behalen van haar master titel, deed ze 
in Portland (Oregon) praktisch onderzoek naar de optimale inrichting van chauffeursca-
bines. Een mooie, interessante tijd en het leverde uiteindelijk een stevige basis voor het 
behalen van haar huidige doctoraat. Corina kreeg hiervoor de kans middels het ‘Groninger 
LCPUFA-onderzoek’ bij de afdeling OntwikkelingsNeurologie van het Universitair Me-
disch Centrum Groningen waarvan u hier de resultaten in handen hebt. 
Corina kreeg in  2011 haar huidige baan, een postdoc-aanstelling bij de afdeling 
huisartsgeneeskunde bij het zelfde UMCG. Haar primaire taak bestaat uit het uitvoeren, 
opzetten en managen van (internationale) onderzoeken met betrekking tot het behandelen 
van longproblematiek binnen de huisartspraktijk. Daarnaast zette zij gedurende drie jaar 
haar onderzoek voor de afdeling OntwikkelingsNeurologie voort en heeft dat nu met dit 
proefschrift afgerond.
Naast wetenschappelijke activiteiten is Corina fanatiek westernruiter en is ze lid 
geworden van de medezeggenschapsraad van de basisschool waar haar zoon naar toe gaat. 
Met het afronden van het onderzoek hoopt ze wat meer tijd te krijgen voor deze activitei-
ten. De wereld ligt aan haar voeten……
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